Epigenetic Silencing Mechanisms In The Humoral Immune Response And Lymphomagenesis by Teater, Matt
EPIGENETIC SILENCING MECHANISMS IN THE HUMORAL IMMUNE 
RESPONSE AND LYMPHOMAGENESIS 
 
 
 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Weill Cornell Graduate School 
of Medical Sciences 
In Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
by 
Matthew R. Teater 
August 2017 
  
  
 
 
 
 
 
 
 
 
 
 
 
© 2017 Matthew R. Teater 
  
EPIGENETIC SILENCING MECHANISMS IN THE HUMORAL IMMUNE 
RESPONSE AND LYMPHOMAGENESIS 
 
Matthew R. Teater, Ph.D. 
Cornell University 2017 
 
A hallmark of diffuse large B cell lymphoma (DLBCL) pathogenesis is the 
perturbation of epigenetic mechanisms.  Germinal center (GC) B cells, from 
which DLBCL originates, are characterized by a specialized phenotype 
enabling rapid proliferation, sustained replicative potential, and tolerance to 
DNA damage.  This GC phenotype facilitates affinity maturation by supporting 
clonal expansion with concurrent mutations and rearrangements of the B cell 
receptor gene.  We found that cytosine methylation patterns in GC B cells 
involve relative loss of methylation and acquisition methylation heterogeneity.  
We found these effects to be largely mediated by AICDA, the enzyme 
responsible for somatic hypermutation of immunoglobulin loci.  In DLBCL, 
expression of AICDA leads to increased epigenetic heterogeneity, a feature 
linked with poor clinical outcome.  The GC phenotype is also mediated in part 
by histone modifications.  We found that the histone methyltransferase EZH2 
is required for GC formation and promotes the GC phenotype by silencing 
proliferation checkpoint and differentiation genes via repressive H3K27me3 
modification of their promoters.  Notably, we found that key regulatory loci 
implicated in GC exit are modified by EZH2 to establish GC-specific bivalent 
chromatin domains.  We found that repression of these GC-specific bivalent 
domains requires cooperation of EZH2 with the BCL6 transcriptional repressor 
and a noncanonical PRC1 complex.  Somatic mutations enhancing the activity 
of EZH2 or BCL6 can “lock in” certain oncogenic features of GC B cells, 
resulting in malignant transformation.  
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CHAPTER ONE: 
INTRODUCTION 
 
1.1 Germinal centers 
During the adaptive humoral immune response, B cells facilitate detection and 
elimination of pathogens by generating long-lived memory B cells (MCs) and 
plasma cells (PCs) with the ability to produce high-affinity antibodies1.  One 
developmental route leading to differentiation of antibody-secreting PCs and 
MCs involves germinal centers (GCs), transient secondary lymphoid organ 
structures that form upon exposure to antigen by infection or immunization2,3.  
Within GCs, B cells compete for affinity-dependent signals, ensuring that B 
cells with higher affinity B cell receptors (BCRs), complexes formed by surface 
immunoglobulin (Ig) and Igα and Igβ co-receptors, are able to progressively 
outcompete B cells with inferior BCRs or those with autoreactive specificities.  
These high-affinity B cell clones subsequently exit the GC and undergo 
terminal differentiation into PCs and MCs. 
 
The formation of GCs begins with acquisition of antigen by mature, naive B 
cells (NBs), followed by migration to the interface between the B cell follicle 
and the T cell zone of a secondary lymphoid organ4,5.  At this interface, NBs 
receive co-stimulatory signals from CD4 helper T cells6,7, triggering a period of 
intense proliferation in which responding B cells relocate preferentially within 
the outer B cell follicle8.  A fraction of these proliferating B cells coalesce into 
tight clusters in the center of the follicle, within close proximity to a network of 
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stromal cells known as follicular dendritic cells (FDCs), giving rise to the early 
GC.  
 
The mature GC is dividend into two compartments: a “dark” zone (DZ), 
representing the GC pole closest to the T cell zone in lymph nodes and 
spleen, and a “light” zone, the pole distal to the T zone and closest to the 
capsule or the marginal zone in lymph nodes or spleen, respectively.  The 
origin of these names refers to the histological appearance seen by 
conventional light microscopy using traditional DNA stains.  The LZ historically 
had appeared “lighter” due to the sparser distribution of lymphocyte nuclei 
among a more abundant stromal network in this compartment9. 
 
The DZ consists primarily of a tight cluster of rapidly proliferating B cells, 
known as centroblasts (CB), which strongly express the chemokine receptor 
CXCR410-13.  Centroblasts have high expression of the enzyme activation-
induced cytidine deaminase (AICDA) and the error-prone DNA polymerase 
eta, which introduces point mutations into DNA when repairing AICDA-induced 
lesions12-14.  This mutagenesis is utilized during proliferation to diversify 
antigen-binding regions of Ig genes via a process called somatic 
hypermutation (SHM).  During SHM, AICDA deaminates deoxycytosines (dCs) 
within the antibody variable V(D)J region, converting them into deoxyuracils 
(dUs) to yield dU:dG mismatches 15-19.  Error-prone repair of these dU:dG 
mismatches can lead to subsequent point mutations and changes in amino 
acid sequence, thereby providing the structural substrate for selection of BCR 
mutants with improved binding to the immunizing antigen 19,20. 
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DZ B cells then move to the LZ, which is less compact and more diverse than 
the DZ.  The LZ contains GC B cells, follicular dendritic cells, a small 
population of follicular helper T (Tfh) cells, and a large proportion of infiltrating 
naïve follicular B cells21.  In contrast to centroblasts, LZ B cells, or centrocytes, 
display an activated phenotype and exhibit higher expression of activation 
markers, such as CD86 and CD83, as well as genes associated with BCR 
pathways12,13,22.  In the LZ, some B cells may undergo class switch 
recombination, wherein AICDA-mediated lesions can facilitate double strand 
breaks and recombination of Ig switch region DNA upstream of constant 
heavy-chain region exons23.  Since such recombination does not change the 
Ig variable region, class switching will not affect antigen specificity, but can 
enable different signaling capabilities due to the extended cytoplasmic tails of 
switched Ig isotypes.  Centrocytes engaging antigen with high-affinity BCRs 
exhibit greater antigen capture and will present a higher density of peptide-
major histocompatibility complexes (MHC) on their surfaces.  This allows high-
affinity B cells to receive more signaling via CD40, B cell-activating factor, and 
Toll-like receptors 1, which transduce via multiple pathways (e.g. mitogen-
activated protein kinase (MAPK) and phosphoinositide 3-kinase), to activate 
the NFκB transcription complex24.  NFκB activation rescues the cells from 
apoptotic pathways by inducing anti-apoptotic genes25.  The NFκB 
transcriptional signature is detectable in a subset of LZ B cells, but is absent in 
the DZ26,27.  Given the presence of antigen, Tfh cells, and an activated 
phenotype, the LZ have been proposed to be the site of selection for high-
affinity antibody variants. 
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Despite their compartmentalization, GCs are dynamic and GC B cells undergo 
rapid flux between the DZ and LZ11,12,21.  Following positive selection, a subset 
of LZ B cells is instructed to recirculate to the DZ.  In the DZ, these 
recirculated B cells undergo further proliferation and SHM, generating 
subclones that potentially feature BCR mutants with further improved affinity.  
The dynamics of selection during affinity maturation have indicated that the LZ 
is constantly repopulated by mass immigration from DZ B cells (at a rate of 
50% of DZ cells transitioning to the LZ over a period of ~4 hours), while less 
than 10% of LZ B cells return to the DZ over a period of 6 hours12.  
Mathematical modeling of these rates estimate that 10-30% of B cells that 
migrate to the LZ are selected to re-enter the DZ28. The remaining B cells will 
either differentiate and exit the GC or will be eliminated by apoptotic 
mechanisms.  Recirculation between the DZ and the LZ facilitates several 
iterative rounds of mutation and selection, thereby promoting the generation of 
high-affinity PCs and MCs (Illustration 1.1). 
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The transcription factor B-cell lymphoma 6 (BCL6), originally identified from 
chromosomal translocations in B cell lymphomas29, is a major regulator of the 
GC reaction29-31.  BCL6 gene expression can be initially detected in the 
interfollicular zone in a small subset of NBs that have successfully undergone 
T-cell-dependent antigen activation32,33.  Although interferon regulatory factor 
8 (IRF8), IRF4, and myocyte-specific enhancer factor 2B (MEF2B) contribute 
to the induction of BCL6 expression34-36, NBs do not produce detectable 
amounts of BCL6 protein37,38.  After activation, however, BCL6 protein is 
abundantly expressed and B cells intrinsically require BCL6 for their 
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development into GC B cells26,29,30,39,40.  BCL6 represses its target genes by  
binding specific DNA motifs and recruitment of histone deacetylase 
complexes, both directly and indirectly via interaction with multiple co- 
repressors41-43.  Within GCs, BCL6 expression is additionally regulated by an 
autoinhibitory mechanism in which the BCL6 protein binds its own promoter to 
repress further transcription44.  BCL6 promotes the GC reaction by repressing 
genes implicated in cell cycle arrest, apoptosis, stress response following DNA 
damage, and B cell differentiation45,46.  A subset of the promoters that are 
targeted by BCL6 in GCBs are also modulated by the repressive histone 
methyltransferase Enhancer of zeste homolog 2 (EZH2), suggesting that these 
two factors may cooperate during transcriptional repression of these genes47.  
 
EZH2, the enzymatic component of Polycomb repressive complex (PRC) 2, is 
critical for normal development and Ezh2 null mice are embryonic lethal48.  In 
embryonic and tissue-specific stem cells, EZH2 plays a major role in 
regulating gene expression patterning critical to the proper coordination of 
differentiation and proliferation49.  Conditional knockout studies in early B cell 
differentiation has also shown EZH2 to be important for normal 
immunoglobulin VDJ recombination50.  However, after the pre-B cell stage, 
EZH2 expression declines and is not detectable in mature B cells until the GC 
reaction47,50,51.  EZH2 is highly upregulated following the GC transition, but is 
downregulated again when B cells differentiate and exit the GC47,52.  Notably, 
EZH2 target genes in GC B cells only partially overlap with EZH2 targets in 
embryonic stem cells, suggesting that EZH2 has GC-specific functions47. 
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In order to exit the GC and undergo terminal differentiation into PCs or MCs, 
GC B cells must repress BCL6 expression.  BCR signaling, induced by high-
affinity interactions with antigen, lead to MAPK-mediated BCL6 
phosphorylation and degradation53 and NFκB induces IRF4, which 
subsequently downregulates BCL6 expression54-56.  The release of BCL6-
mediated silencing allows for IRF4-mediated upregulation of PRDM1, a master 
regulator of terminal B cell differentiation57.  Expression of PRDM1 silences 
the ‘GC B cell transcriptional program’ by repressing several key 
transcriptional factors 58,59 and implements a PC-specific transcriptional 
program60,61, which includes the acquisition of an X-box-binding protein 1 
(XBP1)-dependent antibody-secreting phenotype62. 
 
GC B cells are unique in their ability to replicate at dramatically fast rates11,63 
while undergoing SHM and CSR.  As such, the GC reaction is accompanied 
by suppression of genes involved in sensing or responding to DNA damage 
including ATR, TP53, CHEK1, and CDKN1A64,65.  Additionally, GC B cells 
induce high expression of the enzyme telomerase, ensuring that vigorous 
clonal expansion does not result in telomere shortening and subsequence 
cellular senscence66.  This concurrence of rapid proliferation with prolonged 
replicative potential and tolerance to DNA damage increases the risk of 
oncogenic mutations that can lead to the development of diffuse large B cell 
lymphoma (DLBCL) and follicular lymphoma (FL)67,68. Understanding how B 
cells impose and maintain the GC phenotype may provide important clues that 
could explain the pathogenesis of GC B cell-derived lymphomas.  
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1.2 Diffuse Large B Cell Lymphoma 
B cell non-Hodgkin lymphomas comprise a range of genetically, pathologically, 
and clinically distinct malignancies.  This heterogeneity partially reflects the 
diversity of the B cell system from which the lymphomas originate and the 
multiple pathways of transformation.  The majority of B cell non-Hodgkin 
lymphomas, including Burkitt lymphoma, diffuse large B cell lymphoma 
(DLBCL), and follicular lymphoma (FL), are derived from GC B cells69,70.  
DLBCL is the most common form of B cell non-Hodgkin lymphoma, accounting 
for ~30-40% of newly diagnosed cases of non-Hodgkin lymphoma in 
adulthood71,72.  Despite the common diagnosis, DLBCL itself is also a 
heterogeneous grouping of aggressive B cell lymphomas histologically 
characterized by diffuse proliferation of large neoplastic B-lymphoid cells with 
nuclear size equal to or exceeding normal histiocyte nuclei72.  Gene 
expression profile analyses have classified two principle subtypes of DLBCL: 
GC B cell-like DLCBL (GCB-DLBCL), which is thought to arise from GC light 
zone B cells, and activated B cell-like DLBCL (ABC-DLBCL), which putatively 
originate from later stages of GC differentiation after B cells are committed to 
plasmablastic differentiation13,67.  Patients with ABC-DLBCL subtype have a 
more aggressive clinical course and worse prognosis than those with GCB-
DLBCL subtype67,73. 
 
For decades, the standard treatment approach for DLBCL was 
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) 
chemotherapy74.  The introduction of the chimeric anti-CD20 monoclonal 
antibody rituximab, which specifically targets B cells, to the CHOP regimen 
has greatly improved outcomes for DLBCL patients75, but approximately one-
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third of DLBCL patients will develop either relapsed or refractory disease76.  In 
addition, the median age at DLBCL presentation is in the mid-60s, an 
advanced age that predisposes DLBCL patients to comorbidities that may 
preclude them from tolerating high doses of chemotherapy or receiving stem 
cell transplants.  This underscores the need for novel strategies to improve 
current first line therapies or to establish new and more effective therapeutic 
interventions. 
 
Like most cancers, the mutational landscape of DLBCLs includes numerous 
genetic aberrations including amplifications, deletions, and nonsynonymous 
point mutations associated with gain- or loss-of-function.  One additional 
genetic alteration that is uniquely associated with B cell non-Hodgkin 
lymphomas, particularly DLBCL, is aberrant SHM77.  In normal GCBs, AICDA 
deamination is not restricted to Ig loci and it has been reported that ~25% of 
highly expressed genes can be targeted by SHM78-81.  Such “off-target” activity 
of AICDA is thought to contribute to oncogenic mutation and AICDA has been 
shown to be critical for GC-derived lymphomagenesis82.  Consistent with this, 
over half of DLBCL cases exhibit mutations targeting >10% of transcribed 
genes77,83 (Figure 1.1).  The mutations may occur with both untranslated and 
coding regions, altering regulation or function of the target genes. 
	 10 
 
 
The cellular mechanisms regulating GC formation and maintenance are 
frequently implicated in the malignant transformation into lymphoma.  The 
mutational landscape of GC-derived lymphomas suggests selection of 
epigenetic repression.  Genetic inactivation of transcription co-activators 
acetyltransferse EP300 and/or CREBBP is observed in ~40% of DLBCL84-87.  
Additionally genetic aberrations in histone methyltransferase KMT2D, which 
catalyzes transcriptionally active histone modifications, occur in ~30% of 
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DLBCL cases84-86.  An advantageous role of epigenetic silencing within 
malignant transformation is further supported in the GCB-DLBCL subtype, 
where heterozygous somatic point mutations targeting the EZH2 SET domain 
manifest in ~30% of cases84.  Wild-type (WT) EZH2 displays the greatest 
catalytic activity for monomethylation of H3K27 and relatively weak efficiency 
for subsequent methylation (e.g. mono- to dimethylation or di- to 
trimethylation).  Various point mutations at Y641 in EZH2, however, result in 
an enzyme with limited ability to catalyze the first methylation reaction 
(unmodified H3K27 to monomethylated H3K27), but with enhanced catalytic 
efficiency for the subsequent methylation reactions88,89.  Heterozygous Y641 
mutations may thus work in conjunction with WT EZH2 to increase levels of 
H3K27me388,90.  In accordance with pathogenic advantage to increased PRC2 
repression, EZH2 has also been found to be highly expressed in GC-derived 
lymphomas91 and inactivation (via small molecule inhibition or siRNA 
knockdown) of EZH2 in DLBLC cells causes acute cell cycle arrest at the G1/S 
transition47,92-94.  Overall, the genetic aberrations targeting chromatin-
modifying proteins suggest that lymphomagenesis may favor epigenome 
reprogramming to shift the balance from transcriptionally permissive states 
toward more transcriptionally repressive chromatin modifications (Illustration 
1.2). 
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1.3 Epigenetics: DNA methylation 
DNA methylation describes the process by which methyl groups are covalently 
added to the fifth position of cytosine within a DNA molecule.  Despite not 
altering the primary sequence of DNA, methylated cytosines play an significant 
role in gene silencing95, tissue differentiation96, mammalian development97, 
and X-chromosome inactivation98.  In mammals, the predominant form of DNA 
methylation occurs symmetrically on cytosine residues from both strands of 
cytosine-guanine (CpG) dinucleotides, although cytosine methylation is not 
limited to only CpG sequences99-101.  In human somatic cells, methylated 
cytosines account for ∼1% of total DNA bases and 70–80% of all cytosine-
guanine (CpG) dinucleotides in the genome102.  Notably, CpG dinucleotides 
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are unevenly distributed in the genome, being largely concentrated in small 
genomic regions termed “CpG islands103.”  CpG islands are found within the 
promoters of ~72% of human genes104.  Although promoter-associated CpG 
islands tend to be unmethylated, a subset aquire methylation in specific 
tissues105-107 or developmental stages 108, resulting in transcriptional 
repression of the adjacent genes. 
 
DNA methylation patterns are established during development through a 
highly orchestrated process involving demethylation and de novo methylation 
and can be clonally inherited through the action of maintenance 
methyltransferase activity108-110.  During pre-implantation development, both 
paternal and maternal genomes undergo substantial demethylation, erasing 
the majority of inherited methylation patterns.  Shortly after implantation, the 
embryo undergoes a period of de novo methylation and establishes a 
genome-wide hypermethylation pattern111-114.  In particular, pluripotency genes 
(e.g. Oct4 and Nanog) and CpG island-associated germline-specific genes are 
tightly repressed by DNA methylation, preventing ectopic expression115-123.  De 
novo methylation also occurs during gametogenesis, in both male and female 
germ cells, and is believed to play a critical role to establish genomic 
imprinting, an epigenetic process that yields differential methylation of paternal 
and maternal alleles and monoallelic expression of a small set of genes within 
the offspring108,124,125.  Although de novo methylation activity is present in 
pluripotent cells, it is largely suppressed in differentiated somatic cells and 
subsequent cell type-specific DNA methylation patterns are inherited via 
maintenance DNA methyltransferases114,126-128. 
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Three active cytosine methyltransferases—DNA methyltransferase 1 
(DNMT1), DNMT3A, and DNMT3B—have been identified in humans and 
mice129-131.  DNMT1 is ubiquitously expressed in proliferating cells and 
localizes to DNA replication foci132.  Loss of Dnmt1 in murine ESCs induces 
extensive, nonspecific loss of cytosine methylation127,133.  Furthermore, 
purified DNMT1 protein has strong preference for hemimethylated versus 
unmethylated DNA substrates and is unable to effectively initiate de novo 
methylation in vivo134.  Overall, this suggests that DNMT1 functions primarily 
as a maintenance methyltransferase, responsible for copying the parental 
methylation patterns onto the daughter strand following DNA replication.  In 
contrast, DNMT3A and DNMT3B are strongly expressed in ESCs, early 
embryos, and developing germ cells, but exhibit low expression in 
differentiated somatic cells130,135.  Genetic studies have demonstrated that 
Dnmt3a and Dnmt3b are essential for de novo methylation in murine ESCs, as 
well as for de novo methylation of imprinted genes in the germ cells136,137.  
Although DNMT3A and DNMT3B function primarily to establish methylation 
patterns, they may also required for the maintenance of CpG methylation at 
some loci136,138. 
 
The relationship between cytosine methylation and gene expression is not 
entirely straightforward.  Early observations of inverse correlations between 
gene expression and DNA methylation at CCGG sites in specific genes led to 
hypotheses that DNA methylation played an important role in the silencing 
gene expression139-150.  Although later studies have substantiated a correlation 
between differentially methylated regions near promoters and gene expression 
changes151-155, others have failed to support a major role for DNA methylation 
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in the regulation of gene expression156,157.   Additionally, in cancers most 
aberrantly hypermethyled genes are repressed prior to hypermethylation, 
raising questions of a causal role for methylation in gene repression158-161.  
Furthermore, methylome profiling has revealed that, although expressed 
protein-coding genes generally exhibit low methylation around promoter 
regions, they also possess high methylation over their gene bodies162.  The 
complexity of these patterns suggests that cytosine methylation is unlikely to 
have a clear, binary relationship with transcription. 
 
DNA methylation is also implicated in genomic stability.  Cytosine methylation 
outside of CpG islands is considered a major mechanism for silencing 
repetitive DNA elements, such as transposable DNA sequences or 
endoparasitic sequences, to prevent chromosomal instability, translocations 
and gene disruption163,164.  Studies of murine ESCs deficient for DNMTs 
demonstrated a role for DNA methylation in maintaining telomere integrity165.  
DNMT3B deficiency results in expansion and rearrangements of 
pericentromeric repeats136,166.  Furthermore, reduced DNMT1 activity has 
been implicated in increased microsatellite instability167-171, frequency of 
chromosomal translocations172, and sensitivity to genotoxic agents171, which 
may promote the development of cancer. 
 
During hematopoiesis, DNA methylation contributes to fate decisions in very 
early stages of hematopoietic stem cells as well as subsequent differentiating 
progenitors173,174.  In hematopoietic stem cells from Dnmt1 hypomorphic mice, 
lymphoid, but not myeloerythroid, genes were strikingly suppressed, skewing 
development toward myeloerythroid lineages with impaired B 
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lymphopoiesis175.  Comprehensive methylome mapping further revealed that 
lymphoid lineage commitment relies more on DNA methylation for efficient 
suppression of myeloerthroid genes173,174.  By contrast, Dnmt3a-disrupted 
hematopoietic stem cells strongly favor self-renewal over differentiation toward 
mature cells, a phenomenon exacerbated by combined deletion of 
Dnmt3b176,177.  Among immune cells, DNA methylation profiling between GCB 
and NBs shows a marked shift in patterning, including differential methylation 
of genes affecting the NFκB and MAPK signaling pathways179.  GCBs 
predominantly exhibit loss of methylation compared with NBs and AICDA-
binding sites were highly over-represented among hypomethylated loci.  
Among DNMTs, only DNMT1 is upregulated during the GC reaction and 
Dntm1 hypomorphic mice exhibit deficient GC formation and evidence of 
increased DNA damage179. 
 
DNA methylation patterning is also disrupted during lymphomagenesis179,180.  
DNMT1, DNMT3A, and DNMT3B are overexpressed in 48%, 13%, and 45% of 
DLBCLs and correlate with advanced clinical stages181.  Furthermore, 
concomitant expression of DNMT1 and DNMT3B correlates with resistance to 
treatment, whereas DNMT3B overexpression correlates with shorter overall 
and progression-free survival.  Cytosine methylation profiling studies indicate 
that gene promoter methylation patterning is perturbed in lymphomas 
compared to normal B-cells, and that promoter methylation is generally 
inversely correlated with gene expression182-188. Integrated DNA methylation 
and gene expression profiling can be used to classify ABC- and GCB-
DLBCLs, indicating the subtypes to be epigenetically distinct entities185.  DNA 
methylation profiling in normal B-cell populations, DLBCLs, and FLs also 
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revealed that lymphomas display striking and progressive intra-tumor 
heterogeneity and also inter-patient heterogeneity in their cytosine methylation 
patterns189.  Epigenetic heterogeneity was initiated in normal germinal center 
B-cells, increased markedly with disease aggressiveness, and was associated 
with unfavorable clinical outcome189.  	
In contrast to de novo DNA methylation, the identities of the enzymes in 
humans that catalyze DNA demethylation are largely unknown.  Several 
studies in non-lymphoid tissues have demonstrated that AICDA can participate 
in loss of methylation. AICDA has been implicated in DNA demethylation 
during zebrafish development190, reprogramming in heterokaryons191 and 
pluripotent germ cells192, and late reprogramming of induced pluripotent stem 
cells in mice193.  Although no direct role in DNA demethylation for AICDA has 
been uncovered within in vivo GCBs, hypomethylated regions in GCBs are 
enriched for the putative AICDA binding site RGYW179 and hypomethylation in 
GC-derived lymphomas correlates with AICDA expression189.  As such, AICDA 
has been suggested to induce demethylation via base excision DNA repair of 
deaminated methylcytosines and replacement with unmethylated 
cytosines68,69. 
 
 
1.4 Epigenetics: histone modifications 
In eukaryotic nuclei, genomic DNA is highly folded, constrained, and 
compacted by histone and nonhistone proteins into chromatin.  The basic 
repeating unit of chromatin is the nucleosome, a complex consisting of 
approximately two superhelical turns of DNA wrapped around an octamer of 
	 18 
core histone proteins formed by four histone subunits: an H3-H4 tetramer and 
two H2A-H2B dimers194.  Histones are small basic proteins that are comprised 
of a globular C-terminal domain and a flexible, charged NH2-terminus, known 
as the “tail,” that protrudes out from the nucleosome195,196.  In conjunction with 
linker histone (H1), this chromatin fiber can subsequently twist and fold into 
increasingly more compacted filaments and lead to highr order structures 
(Illustration 1.3). 
 
 
Although histone proteins themselves come in both canonical or nonallelic 
variants with specific expression and localization197, exquisite variation is 
provided by the diverse array of posttranslational modifications that can be 
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covalently added to the histone tail domains (Table 1.1).  Depending on the 
chemical moiety and amino acid position on the tail, histone modifications can 
alter chromatin by modulating histone-DNA contact or provide modification-
specific binding domains for effector proteins198,199.  Several histone 
modifications have additionally been implicated as carriers of epigenetic 
information that can be transmitted through cell division, maintaining gene 
expression patterns within the daughter cells200,201.  There are over 70 
different residues on histones where modifications have been detected either 
by specific antibodies, mass spectrometry, or metabolic-labeling studies202,203 
(Table 1.2).  However, this represents a huge underestimate of the total 
number of potential histone tail modifications and extra complexity is 
introduced by fact that methylation at lysines or arginines may be one of three 
different forms: mono-, di-, or trimethyl for lysines and mono- or di- 
(asymmetric or symmetric) for arginines.  This vast array of modifications gives 
enormous potential for functional responses, but not all modifications occur on 
the same histone simultaneously.  The specific regulation of a modification will 
be dependent on signaling conditions within the cell. 
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Table 1.1	Different Modifications Identified on Histones	
Histone Site Modification Proposed function 
H1 Glu2 ADP ribosylation Unknown 
Glu14 ADP ribosylation Unknown 
Lys26 Methylation Transcriptional silencing 
Ser27 Phosphorylation Transcriptional activation 
H2A Ser1 Phosphorylation Transcriptional repression 
Arg3 Methylation Transcriptional activation, repression 
Lys4 (S. cerevisiae) Acetylation Transcriptional activation 
Lys5 (mammals) Acetylation Transcriptional activation 
Lys7 (S. cerevisiae) Acetylation Transcriptional activation 
Lys9 Biotinylation Unknown 
Lys13 Biotinylation Unknown 
ADP ribosylation Unknown 
Thr119 (D. melanogaster) Phosphorylation Mitosis 
Lys119 (mammals) Ubiquitylation Spermatogenesis 
Thr120 (mammals) Phosphorylation Mitosis, transcriptional repression 
Ser122 (S. cerevisiae) Phosphorylation DNA repair 
Lys126 (S. cerevisiae) Sumoylation Transcriptional repression 
Ser129 (S. cerevisiae) Phosphorylation DNA repair 
Ser139 (mammalian H2A.X) Phosphorylation DNA repair 
Thr142 (mammalian H2A.X) Phosphorylation Apoptosis, DNA repair 
H2B Glu2 ADP ribosylation Unknown 
Lys5 Acetylation Transcriptional activation 
Lys6 (S. cerevisiae) Sumoylation Transcriptional repression 
Lys7 Sumoylation Transcriptional repression 
Ser10 (S. cerevisiae) Phosphorylation Apoptosis 
Lys11 (S. cerevisiae) Acetylation Transcriptional activation 
Lys12 (mammals) Acetylation Transcriptional activation 
Ser14 (vertebrates) Phosphorylation Apoptosis 
Lys15 (mammals) Acetylation Transcriptional activation 
Lys16 (S. cerevisiae) Acetylation Transcriptional activation 
Lys20 Acetylation Transcriptional activation 
Lys30 ADP ribosylation Unknown 
Ser33 (D. melanogaster) Phosphorylation Transcriptional activation 
Ser36 Phosphorylation Transcriptional activation 
Lys120 (mammals) Ubiquitylation Meiosis 
Lys123 (S. cerevisiae) Ubiquitylation Transcriptional activation 
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Table 1.1 (Continued) 
H3 Arg2 Methylation Transcriptional repression 
Thr3 Phosphorylation Mitosis 
Lys4 (S. cerevisiae) Acetylation Transcriptional activation 
Methylation Transcriptional activation 
Biotinylation Gene expression 
Thr6 Phosphorylation Unknown 
Arg8 Methylation Transcriptional activation, repression 
Lys9 Acetylation Transcriptional activation 
Methylation Transcriptional repression 
Biotinylation Gene expression 
Ser10 Phosphorylation Transcriptional activation 
Thr11 (mammals) Phosphorylation Mitosis 
Lys14 Acetylation Transcriptional activation 
Arg17 Methylation Transcriptional activation 
Lys18 Acetylation Transcriptional activation 
Biotinylation Gene expression 
Lys23 Acetylation Transcriptional activation 
Arg26 Methylation Transcriptional activation 
Lys27 Acetylation Transcriptional activation 
Methylation Transcriptional repression 
ADP ribosylation Unknown 
Ser28 (mammals) Phosphorylation Mitosis 
Lys36 Acetylation Transcriptional activation 
Methylation Transcriptional activation 
Lys37 ADP ribosylation Unknown 
Tyr41 Phosphorylation Transcriptional activation 
Arg42 Methylation Transcriptional activation 
Tyr45 Phosphorylation Apoptosis 
Lys56 (S. cerevisiae) Acetylation Transcriptional activation 
Lys79 Methylation Transcriptional activation 
H4 Ser1 Phosphorylation DNA repair 
Arg3 Methylation Transcriptional activation, repression 
Lys5 Acetylation Transcriptional activation 
Lys8 Acetylation Transcriptional activation 
Lys12 Acetylation Transcriptional activation 
Biotinylation DNA damage response 
Lys16 Acetylation Transcriptional activation 
Lys20 Methylation Transcriptional repression 
Lys59 Methylation Transcriptional silencing 
Lys91 (S. cerevisiae) Acetylation Chromatin assembly 
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Large-scale mapping of histone modifications and chromatin-associated 
proteins using chromatin immunoprecipitation combined with high-throughput 
sequencing (ChIPseq) has enabled characterization of both the determinants 
and functional consequences of chromatin structure across the genome in 
diverse cell types.  Two histone modifications, in particular, play crucial 
opposing roles in the epigenetic regulation of numerous developmental genes.  
Methylation of histone H3 lysine 4 (H3K4), catalyzed by the trithorax homolog 
myeloid-lymphoid leukemia (MLL)206, is associated with transcriptional 
activation207-210, whereas trimethylation of H3K27 (H3K27me3), catalyzed by 
the Polycomb-group protein EZH2, is associated with transcriptional 
repression (Illustration 1.4A).  Polycomb-group proteins form the multisubunit 
Polycomb-repressive complexes (PRCs) 1 and 2211,212.  PRC2 catalyzes 
H3K27 methylation, a pivotal mark in the establishment of repressive 
chromatin in both early development and adult organisms213-215.  PRC1 
encompasses a diverse range of complexes that all contain the RING1/RNF2 
ubiquitin ligase and several additional subunits212,216,217.   
 
Polycomb target genes are often jointly occupied and repressed by PRC1 and 
PRC2, in part because H3K27me3 can bind a Polycomb-group Chromobox 
(CBX) family member protein and recruit PRC1.  However, in ESCs, a 
proportion of PRC2 targets are not occupied by PRC1218 and PRC1 has 
capacity to bind genes independently of PRC2219.  Furthermore, even at jointly 
bound promoters, PRC1 and PRC2 act to repress genes independently and 
redundantly220.  Notably, there is a cohort of developmental gene promoters in 
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simultaneous active H3K4me3 and repressive H3K27me3 
modifications218,219,221-224 (Illustration 1.4B).  This pattern of opposing histone 
marks on the same promoter, referred to as “bivalent” domains225, are most 
prevalent in ESCs, but have been observed in cell types of restricted 
potency226,227. By exhibiting both active and repressive features, bivalently 
marked genes “poise” developmental genes, enabling rapid activation upon 
suitable developmental cues while maintaining minimal expression levels in 
the absence of differentiation signals225. 
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During the GC reaction, PRC2 subunits, including the enzymatic subunit 
EZH2, are highly upregulated 52, allowing for the initiation of a repressive 
epigenetic program via addition of H3K27me3 to promoters47.  This GC-
specific repression program that includes silencing of cell cycle checkpoint 
genes and differentiation factors, facilitating rapid proliferation and maturation 
of the GCs47.  In mammals, H3K27 methylation is catalyzed by the SET 
domain of EZH2 and requires the presence of two additional PRC2 subunits, 
embryonic ectoderm development (EED) and suppressor of zeste 12 
(SUZ12)228,229.  
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CHAPTER TWO: 
DNA METHYLATION DYNAMICS DURING GC TRANSITION AND ROLE 
WITHIN GC-DERIVED LYMPHOMAGENESIS*	
 
 
2.1 No correlation between cytosine methylation alterations and gene 
expression changes during GC transition 
Although DNA methylation and gene expression changes are linked in 
pluripotent cells, it is not clear how correlated the relationship is in somatic 
cells.  To investigate the effect of methylation levels on gene expression,  
sorted NBs (CD20+IgD+CD77 ) and GCBs (CD20+IgD CD77+) from reactive 
human tonsils and profiled their methylome using enhanced reduced 
representation sequencing (ERRBS), an efficient single-nucleotide resolution 
high-throughput technique that interrogates 2–4 million distinct CpGs230.  Upon 
rigorous quality control of bisulfite conversion (>99.5% in all samples) and 
read mapping frequency (>70%), we quantified the levels of cytosine 
methylation at represented CpGs in both NB and GCBs.  We found that 
transcriptionally inactive or lowly expressed genes exhibited more methylation 																																																								
∗ Dominguez PM*, Teater M*, Chambwe N, Kormaksson M, Redmond D, Ishii J, Vuong 
B, Chaudhuri J, Melnick A, Vasanthakumar A, Godley LA, Papavasiliou FN, Elemento 
O, Shaknovich R.  (2015) DNA Methylation Dynamics of Germinal Center B Cells Are 
Mediated by AID.  Cell Reports 12(12):2086-98 
∗ Teater M*, Dominguez PM*, Redmond D, Chen Z, Ennishi D, Scott DW, Cimmino L, 
Ghione P, Chaudhuri J, Gascoyne RD, Aifantis I, Inghirami G, Elemento O, Melnick A, 
Shaknovich R. (2017) AICDA drives epigenetic heterogeneity and accelerates 
germinal center-derived lymphomagenesis.  In review 	
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in the region immediately surrounding the transcription start site (TSS), while 
genes with higher expression where depleted for cytosine methylation in these 
regions (Figure 2.1A, B).  Notably, we also found at regions distal to the TSS 
in the gene body, highly expressed genes exhibited more cytosine methylation 
than their lowly expressed counterparts, consistent with previous studies162.  
Although we did not see an obvious difference in the relationship of cytosine 
methylation and transcription between the two cell types, we were interested in 
determine whether the gene expression changes observed during the GC 
transition were correlated with the methylation changes.  To quantify gene 
expression changes during the GC transition, we performed RNA sequencing 
(RNAseq) on sorted human tonsillar NB and GCB populations.  Comparing the 
change in mean methylation within the region ±250bp of TSS (GCB – NB) with 
the log2 ratio of gene expression of GCB compared to NB, we find no 
correlation (Figure 2.1C).  Although we found a subset of genes with alteration 
in cytosine methylation levels in GCB, these genes did not vary in expression 
from GCB to NB.  Similarly, we found that genes that changed expression 
during the GC reaction, where up- or downregulated, had generally constant 
methylation levels.  Overall, we found no correlation between GC changes in 
methylation level at TSS and in expression of the associated genes (Pearson 
correlation coefficient = 0.0346). 
Figure 2.1 
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Figure 2.1 
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2.2 Loss of AICDA abrogates CpG methylation alteration during GC 
transition 
Previous studies observed significant loss of DNA methylation in human GC B 
cells179,231.  To investigate whether AICDA was responsible, at least in part, for 
such a decrease in DNA methylation, we induced T cell-dependent GC 
formation with 4-NP-chicken gamma globulin (NP-CGG) in wild-type (WT; n=7 
replicates) and Aicda-/- (n=6 replicates) mice. Mice were sacrificed at day 10 
post-injection, and splenic NBs (B220+GL7-CD95-) and GC B cells 
(B220+GL7+CD95+) were isolated. We then profiled genome-wide methylation 
changes between respective NB and GC B cells using ERRBS.  Upon rigorous 
quality control of bisulfite conversion (>99.5% in all samples) and read 
mapping frequency (>70%), we called differentially methylated CpGs (DMCs) 
between NBs and GC B cells using a combination of statistical difference 
(false discovery rate [FDR] < 0.001 using Fisher’s exact test) and methylation 
level difference greater than 20%.  We observed that NB to GC B cell 
transition in WT mice was accompanied by significant changes in DNA 
methylation, including 8,308 hypomethylated DMCs (hypo-DMCs) and 3,390 
hypermethylated DMCs (hyper- DMCs) (Figure 2.2A and B).  This is 
consistent with previous results showing a genome-wide loss of methylation in 
primary human GC B cell samples compared to NBs179.  In contrast, our 
profiling of Aicda-/- animals showed minimal changes in DNA methylation 
during the transition from NBs to GC B cells: only 703 of CpGs exhibited 
hypomethylation and 172 CpGs exhibited hypermethylation (Figure 2.2B).  To 
query more comprehensive, global shifts in methylation, including at non-
differentially methylated CpGs, we examined the distribution of methylation 
level changes for all represented CpGs and found that Aicda-/- mice 
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manifested reduced cytosine methylation differences during the NB to GC B 
cell transition, suggesting that loss of AICDA also resulted in less methylome 
plasticity (Figure 2.2C).  This occurred despite comparable ERRBS coverage 
in WT and Aicda-/- cells and similar global methylation levels, as measured 
using liquid chromatography-mass spectrometry (LC-MS), in NBs from WT 
and Aicda-/- mice (Figure 2.2D). LC-MS analysis also revealed higher 
genome-wide levels of 5mC in Aicda-/- GC B cells compared to WT GC B cells 
(Figure 2.2D).  Our results indicate that AICDA is responsible for the majority 
of the methylome changes that B cells undergo during their transit through the 
GC.  
Figure 2.2 
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2.3 AICDA facilitates epigenetic diversity within GC B cells 
We hypothesized that AICDA might also be responsible for the previously 
described increased in methylation diversity within GC B cells compared to 
NBs189.  Taking advantage of the rectilinear properties of “Manhattan” 
distance, we devised a method by which we were able to compare the global 
similarity of any two ERRBS profiles by effectively assessing the number of 
methylation “events” that separated them.  By applying this “pairwise 
methylation distance” metric to all possible pairs among our NB and GCB 
profiles from the WT and Aicda-/- mice, we were able to evaluate the degree of 
epigenetic diversity both among the respective groups and between cell types, 
without limiting the analysis to the smaller set of CpGs re commonly 
represented among all profiles. 
 
We found that WT GC B cell replicates had greater pairwise methylation 
distances to each other than was observed amongst WT NB samples, 
corresponding to higher average methylation diversity (NB WT:GC B cell WT, 
Wilcoxon p = 4.50e-09; Figure 2.3A and B).  This is consistent with epigenetic 
diversification of B cells during their passage through the GC.  Importantly, 
Aicda-/- GCB replicates displayed significantly lower intra-group methylation 
distance than WT GCB replicates (GCB WT:GCB Aicda-/-, Wilcoxon p = 3.59e-
10; Figure 2.3A and B), indicating that loss of AICDA resulted in a more 
homogenous GCB methylome with diversity more akin to that of the Aicda-/- 
NB methylome (NB Aicda-/-:GCB Aicda-/-, Wilcoxon p = 0.000323; Figure 2.3A 
and Figure 2.3B). We also found lower pairwise methylation distance during 
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the transition from Aicda-/- NBs to GCBs than from WT NBs to GCBs 
(Wilcoxon p = 1.76e-20; Figure 2.3A and B).  This decreased diversity is 
consistent with the abrogation of methylation changes during the NB to GCB 
transition observed in AICDA-deficient mice (Figure 2.2).  
Figure 2.3 
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Previous experiments within an ex vivo system showed no cytosine 
methylation changes following depletion or overexpression of AICDA232.  In 
order to reconcile our in vivo AICDA-dependent methylation changes with 
these earlier observations, we activated CD43 - splenic WT cells (NB) in the 
presence of lipopolysaccharide (LPS), interleukin-4 (IL-4), and anti-CD40 and 
infected them with either empty vector (EV) or a vector expressing the full-
length Aicda cDNA (AICDA).  We confirmed by qPCR and western blot that 
the AICDA-overexpressing cells expressed higher levels of AICDA than EV-
infected cells (Figure 2.4A).  Moreover, we detected a higher percentage of 
class-switched splenocytes when AICDA was overexpressed (Figure 2.4B 
and C).  We performed ERRBS profiling on sorted GFP+IgG1+ cells (class-
switched infected cells) and observed few differences in methylation between 
AICDA-overexpressing and EV-infected B cells, with less than 1,000 hyper- 
and hypo-DMCs (Figure 2.4D).  We also calculated the pairwise methylation 
distance between all profiles and found a high degree of homogeneity among 
all sample ERRBS profiles, suggesting that methylation diversity between 
AICDA-overexpressing and EV-infected B cells was similar and comparable to 
the diversity observed in our NB controls (Figure 2.4E).  These results support 
the previous findings obtained by Fritz et al232.  The ex vivo stimulated B cells 
differ from GCBs in that they present significantly reduced levels of SHM—
predominantly targeting the Sµ region—compared to GCBs induced in 
vivo78,233,234.  Reduced SHM and the absence of methylome modification in ex 
vivo activated B cells support the hypothesis of convergence of the 
mechanisms for SHM repair and methylome editing.  
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Figure 2.4 
 
2.4 Methylation changes in Aicda-/- GCBs are not due to changes in the 
cellular composition or clonality within the GC  
In order to rule out the possibility that abrogation of methylation changes in 
Aicda-/- GCBs arises due to changes in the cellular composition within the GC 
(content of CBs versus CCs) or clonal diversity, we carried out detailed 
analysis of GCBs from WT and Aicda-/- animals.  Both WT and Aicda-/- animals 
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had the same proportion of CB (CXCR4high) and CC (CXCR4low) within the GC 
(Figure 2.5A).  To confirm this result, we performed RNAseq on GCBs 
isolated from WT and Aicda-/- mice and compared their expression profiles for 
the genes that constitute the CB (DZ) and CC (LZ) signatures, identified by 
Victora et al.12 (Figure 2.5B).  The expression for these CB- and CC-specific 
genes was highly correlated between WT and Aicda-/- cells (Pearson 
correlation coefficient = 0.984 for DZ genes and 0.989 for LZ genes), 
indicating that both genotypes had comparable gene expression profiles.  In 
addition, we investigated whether there were any differences in clonal 
complexity in the GC between WT and Aicda-/- mice.  For that purpose, we 
amplified rearranged IgH, Igκ, and Igλ regions using primers capturing the 
most abundant families of Ig rearrangements235-237 and performed high-
throughput sequencing using the Illumina MiSeq (PE2x150).  Statistical 
analysis of the Ig rearrangements revealed no significant difference in clonal 
complexity and or composition of VH regions between WT GCBs and Aicda-/- 
GCBs (Wilcoxon p=0.8571; Figure 2.5C).  Furthermore, we observed no 
differences in the cell-cycle distribution based on bromodeoxyuridine (BrdU) 
incorporation and 7-AAD staining of GCBs from WT and Aicda-/- mice (Figure 
2.5D).  Altogether, these findings indicate that the composition and the 
clonality of WT and AICDA-deficient GCBs are equivalent. 
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Figure 2.5 
 
2.5 AICDA-dependent hypomethylation in GC B cells is enriched to occur 
at SHM hotspot genes and dsDNA breaks 
To investigate the genomic distribution of AICDA-dependent methylation 
changes, we defined AICDA-dependent hypo- and hyper-DMCs as CpGs that 
are hypomethylated (blue rectangle, Figure 2.6A) or hypermethylated (yellow 
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rectangle, Figure 2.6A) during NB to GCB transition in WT animals but show 
no respective differential methylation changes in Aicda-/- animals.  We found 
that these AICDA-dependent hypo- and hyper-DMCs were significantly 
depleted in promoters of genes and enriched in introns and intergenic areas 
(Fisher’s exact test, p < 0.001; Figure 2.6B).  AICDA-dependent hypo- and 
hyper-DMCs were also depleted in CpG islands, shores, and shelves and 
enriched in inter-island regions (Fisher’s exact test, p < 0.001; Figure 2.6C).  
Since AICDA-dependent DNA demethylation is thought to occur via 
deamination and subsequent DNA repair, similar to SHM, we investigated 
whether AICDA-dependent DMCs were enriched in genes reported to be 
targets of SHM in GCBs78.  Notably, AICDA-dependent hypo-DMCs were 
enriched in occur within SHM hotspot genes (Fisher’s exact test, p < 0.001; 
Figure 2.6D).  As SHM occurs at highly expressed genes, we also tested if 
AICDA-dependent DMCs were enriched in genes highly expressed in WT 
GCBs (fragments per kilobase of transcript per million mapped reads (FPKM) 
> 20). We found no enrichment for hypo-DMCs (data not shown), suggesting 
that hypomethylation results from AICDA targeting specific genomic loci, not 
simply as a consequence of open chromatin structure or regions with high 
transcriptional activity.  We also found enrichment of AICDA-dependent hypo-
DMCs in AICDA-associated double-stranded DNA (dsDNA) breaks identified 
using high-throughput genomic translocation sequencing238 (Fisher’s exact 
test, p < 0.001; Figure 2.6D) and in loci associated with double-strand breaks 
defined through γ-H2AX occupancy239 (Fisher’s exact test, p < 0.001; Figure 
2.6D), suggesting an association between AICDA-dependent hypomethylation 
and DNA breaks.  
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Figure 2.6 
 
The AICDA/APOBEC family of proteins has been known to contribute to 
intrinsic immunity against retrotransposition of endogenous and exogenous 
retroviruses240.  Endogenous retroviruses are present in multiple copies in 
mammalian genomes and constitute up to a staggering 8% of human and 
mouse genomic DNA 241,242. As AICDA-dependent DMCs are enriched in 
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Figure 2.6.  AICDA-dependent DNA methylation changes show characteristic distribution.  (A) 
Scatterplot comparing delta methylation (GCB% - NB%) of WT versus Aicda-/- mice. AICDA-dependent 
hypo-DMCs are indicated by a yellow dashed box and hyper-DMCs by a blue dashed box.  (B) Bar plot 
showing genomic distribution of AICDA-dependent hypo-DMCs and hyper-DMCs as well as all CpGs 
represented within ERRBS experiments. AICDA-dependent DMCs are depleted within promoters and 
over-represented in introns and distal and intergenic regions.  (C) Bar plot showing the distribution of 
AICDA-dependent hypo-DMCs and hyper-DMCs within CpG islands, shores, shelves, and inter-island 
regions. AICDA-dependent DMCs are depleted in CpG islands, shores, and shelves and enriched in 
inter-island regions. (D) Fraction of AICDA-dependent DMCs enriched in SHM hotspot genes, AICDA-
mediated dsDNA breaks, and loci with γH2AX occupancy (*p < 0.05, **p < 0.01, and ***p < 0.001).
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introns and intergenic regions (Figure 2.6B), we investigated whether AICDA 
targets repetitive elements present in those regions of the genome. We 
annotated our AICDA-dependent DMCs according to RepeatMasker and 
identified six intergenic repetitive elements that were significantly enriched for 
the presence of AICDA-dependent DMCs, including L1 repeat element, 
IAPEY3_LTR, and MLT1J1 (Figure 2.7A). We also found two intragenic 
repetitive elements that were significantly enriched to contain AICDA-
dependent DMCs (Figure 2.7B). In summary, although we do find cases of 
enrichment at specific repetitive elements, AICDA appears to acts mostly upon 
non-repetitive DNA sequences.  
igure 2.7 
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Figure 2.7.  AICDA-dependent changes in DNA methylation targeting repetitive elements.  (A)
Volcano plot identifying intergenic repeats enriched for AICDA-dependent DMCs. Red lines indicate 
thresholds for two-fold enrichment versus all represented CpGs and Bonferroni-corrected p<0.05. 
(B) Volcano plot identifying intragenic repeats enriched for AICDA-dependent DMCs.
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2.6 Epigenetic function of AICDA is conserved between human and 
murine GC B cells 
We next investigated if, similar to SHM targets, there were hotspots of AICDA 
epigenetic activity in GCBs.  In order to identify such ‘‘epigenetic hotspots,’’ we 
looked for differentially methylated regions (DMRs) based on the presence of 
at least five DMCs, a maximum distance of 250kb between DMCs, and at least 
10% difference between average methylation within the region.  We identified 
119 DMRs between NBs and GCBs from WT mice, distributed throughout all 
chromosomes and consisting predominantly of hypo-DMRs (Figure 2.8A).  
We observed that these DMRs were mostly AICDA-dependent, and 88 hypo- 
DMRs and 16 hyper-DMRs were lost in Aicda-/- animals (Figure 2.8A), in 
agreement with our results from the analysis of DMCs (Figure 2.2). 
 
To investigate whether the AICDA epigenetic program in mouse GC was 
conserved in human GC, we examined human tonsillar NB and GCB profiles.  
Using the same criteria applied to mouse data to call DMCs, we confirmed that 
human GCBs also underwent extensive hypomethylation compared to NBs 
and displayed greater epigenetic diversity than NBs (Figure 2.8B and C). 
Although we identified a greater number of DMCs in the human NB to GCB 
transition (69,277 hypo-DMCs and 5,991 hyper-DMCs), the genome-wide 
distribution of human DMCs was very similar to the distribution of murine 
DMCs, with enrichment in introns and depletion in promoters, CpG islands, 
and CpG shelves (Figure 2.8D and E).  To address whether the methylation 
changes underlying the GC transition in human cells affected the same 
AICDA-epigenetic targets as in murine cells, we characterized DMRs between 
human NBs and GCBs, applying the same criteria used in mouse samples, 
	 40 
and assessed the significance of overlap between orthologs of murine genes 
associated with AICDA-dependent DMRs and human genes associated with 
DMRs.  Remarkably, we observed a significant overlap between murine 
AICDA-dependent hypo-DMR-associated gene orthologs and human genes 
associated with hypo-DMRs (hypergeometric p = 5.73e-08; Figure 2.8F).  The 
comparability of epigenetic reprogramming between mouse and human GC 
suggests that epigenetic changes associated with the NB to GCB transition 
are conserved between species, similar to conservation of the transcriptional 
programming. 
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Figure 2.8 
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Figure 2.8. Conserved epigenetic function of AICDA between human and murine B cells.  (A) Ideogram of 
DMRs in WT (left) and Aicda-/- (right) cells showing depletion of DMRs in Aicda-/- cells. Hypo-DMRs are indicated in 
blue, and hyper-DMRs are indicated in yellow.  (B) Combined CpG methylation values (top) and DMCs (bottom) 
between NBs and GCBs from human tonsils (four replicates) determined by ERRBS using a 20% methylation 
difference threshold and FDR < 0.001 (Fisher’s exact test). Hypomethylated CpGs are indicated in blue, and 
hypermethylated CpGs are indicated in yellow.  (C) Heatmap showing pairwise methylation distance between ERRBS 
profiles of NB and GCB replicates from human tonsils with GCBs showing greater intra-group methylation distance 
(green versus yellow).  (D) Bar plot showing genomic distribution of hypo-DMCs and hyper-DMCs as well as all CpGs 
represented within ERRBS experiments. DMCs show depletion in promoters and enrichment in introns and distal and 
intergenic regions.  (E) Bar plot showing distribution of DMCs within CpG islands, shores, shelves, and inter-island
regions.  (F) Heatmap showing overrepresentation of murine AICDA-dependent hypo-DMR-associated orthologs
with human hypo-DMR-associated genes (*p < 0.05, **p < 0.01, and ***p < 0.001).
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2.7 Loss of AICDA in GCB reduces DNA methylation heterogeneity and 
causes relative gain in methylation 
As we observed AICDA to be implicated two interrelated aspects of cytosine 
methylation patterning (cytosine hypomethylation and cytosine methylation 
diversity), we sought to identify AICDA cytosine methylation heterogeneity 
signatures in a comprehensive and unbiased manner.  To this end, we 
performed a principal component analysis (PCA) on all CpGs according to 
these two dimensions of AICDA-associated changes: change in mean 
methylation level and the change in “spread” of methylation values, measured 
as interquartile range (IQR), between respective Aicda-/- GCB and WT GCB 
(Figure 2.9A).  This analysis found that, consistent with the results from 
Figure 2.2, the most pronounced alteration to the GCB Aicda-/- methylome 
involved a relative gain of methylation and decreased heterogeneity between 
individuals (Figure 2.9B).  Using the component loading factor from this 
approach, we identified an AICDA cytosine methylation signature containing 
64,323 CpGs (GCB AICDA-perturbed CpGs; Figure 2.9B).   
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Figure 2.9 
We found the GCB AICDA-perturbed signature to be comprised of CpGs that 
gained methylation, primarily from a highly methylated state within WT controls 
(Figure 2.10A).  The signature CpGs also exhibited a loss of inter-individual 
heterogeneity among Aicda-/- GCBs (median WT GCB IQR = 17.35%; median 
Aicda-/- GCB IQR = 4.89%; Figure 2.10B).  Notably, the gain of methylation in 
this signature resulted in a reduction of intra-individual heterogeneity 
compared to WT (paired Wilcoxon test p<1e-300; Figure 2.10C), as many 
CpGs exhibited a uniformly methylated state in Aicda-/- GCBs in contrast to a 
more mosaic highly methylated state in WT GCBs.  Consistent with the 
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Figure 2.9.  Multidimensional integrated analysis of methylation.  (A) Density scatterplot showing 
centered data representing change in mean methylation level versus change in IQR between Aicda-/- 
and wild-type GC B cells.  The blue line indicates the principal component axis.  (B) Principal component
decomposition of centered data from (A).  Top, principal component (PC) scores indicating methylation 
pattern manifesting increase in methylation and decrease in inter-individual heterogeneity within Aicda-/- 
GC B cells relative to wild-type controls.  Bottom, ranked CpG component loading factors.  Horizontal 
black line indicates mean loading factor and blue rectangle indicates AICDA perturbation CpG signature.
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genomic distribution of AICDA-depednt hypoDMCs, we found these signature 
CpGs to be significantly depleted from gene promoters and highly enriched 
within introns and intergenic regions (Fisher’s exact test p<0.001; Figure 
2.10D).  We also found this signature to be largely depleted from CpG islands, 
but were slightly enriched with CpG “shelves” (Fisher’s exact test p<0.001; 
Figure 2.10E).  
Figure 2.10 
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2.8 Overexpression of AICDA in GC-derived lymphomas results in more 
aggressive disease 
To characterize the actions of AICDA in GC-derived lymphomagenesis, we 
transplanted bone marrow cells from VavP-Bcl2 transgenic mice transfected 
with AICDA expressing retrovirus (VavP-Bcl2+Aicda) or empty vector control 
(VavP-Bcl2) into lethally irradiated recipients.  All mice were sacrificed after 
eight months, the timepoint at which VavP-Bcl2+Aicda animals presented 
signs of morbidity. Histopathological examination revealed more aggressive 
disease in VavP-Bcl2+Aicda (n=8) than in VavP-Bcl2 (n=7) mice, with greater 
disruption of splenic architecture and neoplastic B cell expansion in organs 
such as lung, liver and kidney (Figure 2.11A).  Reminiscent of human 
DLBCLs, the spleens of VavP-Bcl2+Aicda but not VavP-Bcl2 control mice 
exhibited white pulp expansion with replacement by sheets of neoplastic B-
cells (Figure 2.11A).  The VavP-Bcl2+Aicda neoplastic cells were larger, 
exhibited greater pleomorphic morphology and had higher Ki-67 positivity 
(Figure 2.11B), indicating increased number of proliferating cells, a feature 
that is correlated with more aggressive DLBCL243.  Necropsy of diseased 
animals revealed greater burden of disease in spleen, lung, kidney, and livers 
of VavP-Bcl2+Aicda animals, as quantified by the degree of neoplastic 
expansion and infiltration (Figure 2.11C).  A separate cohort of mice was 
followed longitudinally to assess impact of AICDA expression on survival. 
VavP-Bcl2+Aicda mice (n=10) manifested significantly shortened lifespan 
(Log-rank test P=0.0289), with a median survival of 214 days as opposed to 
293 days for VavP-Bcl2 (n=9) animals (Figure 2.11D).  Hence, AICDA 
overexpression was associated with a more aggressive disease phenotype 
and decreased survival. 
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Figure 2.11 
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2.9 AICDA overexpression induces DNA methylation heterogeneity and 
hypomethylation, but no increase in somatic mutation burden 
To explore whether AICDA-overexpressing lymphomas manifested cytosine 
methylation pattern differences, we performed ERRBS on VavP-Bcl2+Aicda 
(n=7) and VavP-Bcl2 (n=6) lymphoma B cell populations. Initial examination of 
global methylation levels indicated that VavP-Bcl2+Aicda tumors showed 
fewer highly methylated CpGs, consistent with the role of AICDA in 
demethylation (Fisher’s exact test p=2.27e-14; Figure 2.12A).  To interrogate 
whether VavP-Bcl2+Aicda tumors also exhibited more diverse cytosine 
methylation patterning, we examined pairwise methylation distance between 
cytosine methylation profiles and found that VavP-Bcl2+Aicda lymphomas 
indeed manifested greater global inter-tumor heterogeneity than their VavP-
Bcl2 counterparts (Wilcoxon p=0.00112; Figure 2.12B).  Since AICDA induces 
DNA hypomethylation in GC B-cells, we postulated that the AICDA-mediated 
DNA methylation heterogeneity would be more prominently observed among 
hypomethylated cytosines in VavP-Bcl2+Aicda lymphoma cells.  We therefore 
evaluated two-dimensional AICDA-associated changes (mean methylation 
level and IQR) between respective tumors, at each CpG showing >20% 
methylation difference.  Among these selected CpGs, inter-tumor 
heterogeneity was significantly associated with hypomethylation in VavP-
Bcl2+Aicda mice compared to control mice (Fisher exact test p=3.68e-40; 
Figure 2.12C).  
 
Using PCA to identify an AICDA cytosine methylation signature, we found that, 
inverse and reciprocal to the results from AICDA depletion, the most 
pronounced alteration caused by AICDA overexpression within the VavP-Bcl2 
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methylome involved methylation loss and increased inter-tumor heterogeneity.   
We identified a VavP-Bcl2+Aicda cytosine methylation signature containing 
49,750 CpGs (VavP-Bcl2 AICDA-perturbed CpGs).  This signature was 
comprised of CpGs that lost methylation, primarily from a highly methylated 
state within VavP-Bcl2 controls (Figure 2.12D).  The signature CpGs also 
exhibited increased inter-tumor heterogeneity among the VavP-Bcl2+Aicda 
lymphomas, compared to relatively stable methylation states within VavP-Bcl2 
controls (median VavP-Bcl2 IQR = 5.56%; median VavP-Bcl2+Aicda IQR = 
19.2%; Figure 2.12E).  The loss of methylation of this VavP-Bcl2+Aicda 
cytosine methylation signature also resulted in a relative increase in intra-
tumor heterogeneity compared to the VavP-Bcl2 tumors (paired Wilcoxon test 
p<1e-300; Figure 2.12F).  VavP-Bcl2+Aicda-perturbed CpGs were 
significantly depleted from gene promoters, but were highly enriched within 
introns and intergenic regions (Fisher’s Exact Test p<0.001; Figure 2.12G).   
VavP-Bcl2+Aicda-perturbed CpGs were also largely depleted within CpG 
islands, but were slightly enriched within CpG “shores” and “shelves” (Fisher’s 
Exact Test p<0.001; Figure 2.12H).  These AICDA-mediated epigenetic 
changes are unlikely to stem from differences in the proliferation rate between 
AICDA-overexpressing and control lymphomas since DNA methylation 
heterogeneity in lymphoma cells is independent of the mitotic ratio189.  Given 
the similar genomic distribution and reciprocal nature of epigenetic effects 
between Aicda loss and overexpression, respectively, in normal and malignant 
B-cells, we investigated whether AICDA preferentially affected the same 
genes within the two systems.  Indeed, there was statistically significant 
overlap between genes enriched for VavP-Bcl2 tumor AICDA signature CpGs 
	 49 
within gene bodies and genes over-representing GC Aicda-/- signature CpGs 
within gene bodies (hypergeometric test p=1.98e-121, Figure 2.12I).  
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Figure 2.12 
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2.10 AICDA overexpression does not increase somatic mutation burden 
Overexpression of AICDA could also contribute to lymphomagenesis by 
introducing somatic mutations at non-Ig loci, such as proto-oncogenes. To 
evaluate the contribution of AICDA mutational activity to the aggressive 
phenotype observed in VavP-Bcl2+Aicda mice, we first assessd the mutational 
burden of known Ig (JH4 and Sµ) and non-Ig loci (Bcl6, Cd83 and Pax5) using 
targeted resequencing.  We observed no significant differences in burden of 
non-synonymous mutations (Figure 2.13A) or indels (Figure 2.13B) within Ig 
loci, Cd83, or Pax5, although indels were enriched at the Bcl6 locus in VavP-
Bcl2+Aicda mice.  To further explore genomic effects of AICDA 
overexpression, we performed whole exome sequencing in VavP-Bcl2+Aicda 
(n=4) and VavP-Bcl2 lymphomas (n=4) and found no significant difference in 
non-synonymous or indel mutation burdens (Figure 2.13C and D).  These 
data suggest that the more aggressive VavP-Bcl2+Aicda phenotype is not 
significantly associated with increased mutational burden.  Hence, 
overexpression of AICDA in B-cell lymphomas induces increased burden of 
epigenetic changes, without significant change in the burden of somatic 
mutation compared to lymphomas with endogenous AICDA levels, 
recapitulating earlier evidence that the level of AICDA expression did not 
increase aberrant SHM in DLBCL244. 
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Figure 2.13 
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2.11 High expression of AICDA in DLBCL is associated with higher DNA 
methylation heterogeneity and hypomethylation 
To investigate whether AICDA cytosine methylation signatures can be 
detected in primary human lymphomas, we performed ERRBS and RNAseq in 
a cohort of 63 primary DLBCL patients. We compared cases with the highest 
AICDA expression (>50 CPM; AICDA-high DLBCL; n=10) against the cases 
with lowest or no AICDA expression (<2 CPM; AICDA-low DLBCL; n=19, 
Figure 2.14A).  Similar to mouse VavP-Bcl2+Aicda lymphomas, we found that 
AICDA-high DLBCL patients manifested greater global inter-tumor 
heterogeneity than AICDA-low cases (Wilcoxon p=4.17e-06; Figure 2.14B).  
Given the concordance of these results with our previous murine findings, we 
performed a PCA to determine if higher levels of AICDA would have similar 
consequences upon the DLBCL methylome.  Indeed, AICDA-high DLBCLs 
exhibited a pattern of increased inter-tumor heterogeneity and 
hypomethylation compared to DLBCL profiles with low expression of AICDA.  
From this PCA, we identified a DLBCL AICDA-high methylation signature 
(n=37,557 DLBCL AICDA-perturbed CpG) that exhibited similar methylation 
dynamics to VavP-Bcl2+Aicda (and opposite to Aicda-/- GC B-cells), including 
loss of CpG methylation from intermediate and highly methylated states 
(Figure 2.14C) alongside gain of inter-tumor methylation heterogeneity 
(Figure 2.14D).  We also found that the AICDA-high DLBCLs had higher intra-
tumor methylation heterogeneity compared to their lower AICDA-expressing 
controls (paired Wilcoxon p=5.22e-229; Figure 2.14E).  This CpG signature 
was depleted in gene promoters and enriched in exons, introns, and distal 
regions (Fisher’s exact test p<0.001; Figure 2.14F).  AICDA-high DLBCL 
perturbed CpGs were also under-represented in CpG islands and enriched in 
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CpG “shelves” and “shores” (Fisher’s exact test p<0.001; Figure 2.14G). 
Notably, we found significant overlap of gene orthologs affected by AICDA-
perturbed CpGs in human AICDA high DLBCLs and murine VavP-
Bcl2+AICDA lymphomas (hypergeometric p=2.21e-23; Figure 2.14H) and with 
the gene orthologs affected by AICDA in normal GC B-cells (hypergeometric 
p=8.48e-33; Figure 2.14H).  To assess whether this high AICDA-perturbed 
cytosine methylation signature was associated with DLBCL subtype, we 
categorized our AICDA-high and AICDA-low DLBCL cases according to their 
gene expression67.  Despite presumably reflecting late or post-GC B-cells, we 
found that AICDA-high DLBCL were more likely to be classified as ABC-
subtype than AICDA-low DLBCL (Fisher’s exact test p=0.021; Figure 2.14I).  
This is consistent with previous reports that AICDA is more highly expressed 
in ABC-DLBCL244,245 and that epigenetic heterogeneity is more pronounced in 
the ABC-subset of DLBCL189.  
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Figure 2.14 
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2.12 Notes on analysis 
Although quantification of inter-tumor heterogeneity at individual CpGs via IQR 
or standard deviation is relatively straightforward, quantification of inter-tumor 
heterogeneity between global ERRBS profiles is substantially more difficult.  
Many ERRBS profiles are disproportionately weighted with uniformly 
methylated or unmethylated CpGs.  This makes comparison of CpG IQR 
distributions between groups problematic as low heterogeneity CpGs 
overwhelm the distribution and may lead to false negatives (Figure 2.15A).  
This problem can be overcome using statistical procedures that reduce 
dimensionality, e.g. principal component analysis, as low variance CpGs will 
not contribute meaningfully to the first few principal components (PCs).  
Subsequent comparison of samples using Euclidean distance within the space 
defined by PC vectors with greatest variance permits evaluation of the inter-
tumor heterogeneity of ERRBS profiles (Figure 2.15B).  Such PC space 
distance approaches, however, still have a number of limitations.  The 
interpretation of distance metrics within low-dimensional orthogonally 
transformed space can be difficult.  Also, given their inability to tolerate 
missing data, only CpGs represented in all ERRBS profiles can be evaluated, 
potentially leading to omission of relevant data.  Additionally, this approach is 
fragile to outliers within the data.  Gross errors in methylation values for even a 
few CpGs can have a disproportionate weight on variance within the data and 
designation of the first PC (Figure 2.15C).  As each successive PC vector is 
independent and orthogonal to preceding PC vectors, such outliers will drive 
the PC space and may lead to artificial increase or decrease within 
heterogeneity measurements.  Our “pairwise methylation distance” approach 
addresses these issues by evaluating Manhattan distance on the full-
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dimensionality of the data.  The contribution of low heterogeneity or uniform 
CpGs is minimized, as they will not contribution greatly to the overall distance.  
Furthermore, given the rectilinear properties of Manhattan distance, 
interpretation is intuitive and the resulting distance value can be construed as 
the number of methylation “events” that separate the respective sample pair.  
Also, we can evaluate the similarity of methylation values at all CpGs common 
just to the two ERRBS profiles under comparison, regardless of whether they 
are represented in every other profile.  By normalizing the resulting Manhattan 
distance to 106 CpGs, we are able to evaluate the distribution of pairwise 
methylation distances between relevant groups (e.g. high AICDA expression 
versus low AICDA expression) to assess differences in inter-tumor 
heterogeneity (Figure 2.12B, 2.14B). 
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Many contemporary analytical approaches exist that assess differential 
cytosine methylation changes levels or changes in cytosine methylation 
heterogeneity, either inter-sample (e.g. variance or IQR) or intra-sample 
(typically via entropy-based methods on four-CpG segments on bisulfite 
sequencing reads).  These approaches, however, treat changes in methylation 
levels as separate and independent from changes in methylation 
heterogeneity.  This assumption is erroneous, as methylation heterogeneity is 
generated by non-uniform gain or loss of methylation at CpGs.  Recognizing 
the interconnected nature of cytosine hypomethylation and AICDA-mediated 
increase in inter-sample heterogeneity, we devised an approach that accounts 
for both changes in mean methylation level and change in inter-tumor 
heterogeneity.  Using an unconventional application of principal component 
analysis, we were able to determine the linear combination of alterations in 
methylation level and “spread” associated with the overexpression of AICDA.  
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Additionally, by using the decomposed PC loadings as a measure of the 
weight each CpG contributes to the overall pattern of hypomethylation and 
inter-tumor methylation heterogeneity gain, we were able to identify a 
signature of CpGs that best drive the cytosine methylation alterations we 
observe from AICDA overexpression. 
 
2.13 Discussion 
We have demonstrated using a genome-wide approach that B cell transit 
through the GC is accompanied by locus-specific hypomethylation and minor 
gains of methylation, along with a substantial increase in DNA methylation 
diversity.  More importantly, our results indicate that such changes are largely 
mediated by AICDA. In the last decade, we have gained in-depth knowledge 
regarding the function of epigenetic alterations in normal development and 
cancer biology.  DNA methylation is understood to play a key role in gene 
imprinting, X chromosome inactivation, and regulation of gene expression 
specific to tissue identity, developmental stage, and cell lineage246,247.  
Changes in the DNA methylome mark specific stages of B cell ontogeny and 
play an important role in B cell lymphomagenesis185,189,231,248-251.  The GC 
stage of B cell development is associated with a proliferative burst, affinity 
maturation of B cells with associated SHM and CSR, all of which contribute to 
adaptive immune response and determine antibody diversity68, but the 
contribution of the methylome to these processes is not clearly defined.  It has 
been demonstrated that changes in methylation are required for the successful 
formation of the GC and that such modifications are dependent on DNMT1, a 
methyltransferase highly expressed in GCBs179.  While the mechanism of DNA 
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methylation gain is well understood, the mechanism of demethylation, the 
factors responsible for the loss of methylation in GCBs, and its biological 
significance remain almost completely unknown.  Since AICDA is highly 
expressed in GCBs and has been implicated in DNA demethylation during 
embryonic development and epigenetic reprogramming190-193, we 
hypothesized that AICDA is involved in the active demethylation of B cells 
during GC transition.  
 
To prove this hypothesis, we isolated NBs and GCBs from in vivo WT and 
Aicda-/- mice and profiled their methylome using ERRBS, a genome-wide 
approach capable of interrogating three million CpGs.  We observed that over 
90% of methylome alterations characterizing the transition from NBs to GCBs 
were lost in Aicda-/- animals, confirming the role of AICDA in the DNA 
demethylation of the GCB genome.  We also found that AICDA depletion 
caused loss of hypermethylation in GCBs.  We suspect this to be a result of 
reduced recruitment of DNMT1 to double-strand breaks252, putatively 
generated as a consequence of the AICDA deamination activity253.  Several 
prior attempts to link AICDA to demethylation in GCBs were made before.  
Fritz et al. addressed this same question using an ex vivo system, activating 
primary splenocytes in the presence of anti-CD40, LPS, and IL-4232.  The 
authors could not detect AICDA-induced changes in the B cell methylome, 
consistent with our results with ex vivo stimulated B cells.  This suggests that 
AICDA-dependent demethylation requires additional factors and is perhaps 
coupled to the rate of SHM, which is much lower in the ex vivo system than in 
GCBs233,234.  In this regard, it has recently been demonstrated that ex vivo 
stimulated B cells are defective in SHM because the initiating form of RNA 
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polymerase II is not retained in the variable regions of the Ig genes, 
hampering the recruitment of the cofactor Spt5 and AICDA254.  Another 
attempt to delineate the demethylation function of AICDA in GCBs was made 
by Hogenbirk et al. using MethylCap sequencing (MethylCap-seq) and failed 
to find any AICDA-dependent changes255.  MethylCap-seq is an affinity-
purification-based technique, which is likely not to be sufficiently sensitive to 
detect variable methylation changes in CpGs scattered throughout genome.  
Here, we have used ERRBS, a genome-wide technique with higher coverage 
compared to MethylCap-seq and single-nucleotide-level resolution256.  We 
think that the above differences are due to the experimental system and the 
techniques used in earlier studies.  
 
Importantly, we have demonstrated that the epigenetic diversification of the B 
cell methylome during GC transition is dependent on AICDA activity.  It is 
tempting to speculate that this methylation diversification may contribute, 
along with SHM, to clonal evolution among normal GCBs.  We show here that 
the genomic distribution of hypo-DMRs in GCBs is similar to the distribution of 
AICDA binding sites revealed by Liu et al78.  We also provide circumstantial 
evidence that the demethylase function of AICDA may arise from its 
deaminase activity, showing that AICDA-dependent hypo-DMCs are enriched 
within known AICDA target genes for SHM.  Despite expectation that AICDA-
dependent differential methylation would be concentrated around transcription 
start sites (TSSs) of genes, similar to SHM hotspots, our data reveal that 
DMCs are enriched in gene introns and intergenic regions.  This is consistent 
with the location of AICDA-dependent demethylation observed in other 
systems192,193.  We also found enrichment of AICDA-dependent hypo-DMCs at 
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loci associated with dsDNA breaks.  It is possible that, despite the intense 
focus on SHM target genes, AICDA may bind genome-wide, with the majority 
of binding similarly distributed outside of TSS and gene bodies.  This would 
suggest AICDA deamination activity to have more far-reaching consequences 
than we have yet appreciated.  It has been proposed that AICDA-dependent 
regions of demethylation may extend beyond the deamination sites as a result 
of the activity of processive DNA repair pathways (mismatch repair or long-
patch base excision repair).  These pathways can result in the replacement of 
long stretches of DNA (up to 2 kb) with concomitant possible repair of all 
somatic mutations257.  Such broad extension of hypomethylation could, in turn, 
have various consequences, including instability of transposable elements, 
chromosomal translocations, and gene deregulation, as suggested by Guadet 
et al258. 
 
Although AICDA loss abrogates the majority of the methylation changes 
experienced by GCB, we observe residual hypomethylation in Aicda-/- GCBs, 
suggesting that other demethylation mechanisms are likely to exist in these 
cells.  The most plausible scenario is TET-dependent oxidative demethylation, 
which has been proposed as an alternative to AICDA deamination-dependent 
demethylation259.  Another source of demethylation may be passive loss of 
methylation in highly proliferative GCBs.  The fact that Aicda-/- GCBs are 
highly proliferative, and nevertheless have minimal loss of methylation, argues 
against this theory.  Moreover, passive stochastic loss of methylation would 
likely be randomly distributed throughout the genome, and our results show 
preferential genomic distribution of the methylation changes.  
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Our work additionally suggests that AICDA is a critical source of epigenetic 
plasticity and heterogeneity in DLBCL.  We find that AICDA-linked epigenetic 
heterogeneity is predominantly associated with relative loss of cytosine 
methylation, consistent with the known mechanism of action of AICDA in 
cytosine deamination.  Although AICDA targeting seems to show preference 
for certain chromatin features, we anticipate that the effect on specific 
cytosines will likely be stochastic, resulting in gradual divergence of 
methylation landscapes between cells. Consistent with the known association 
of cytosine methylation heterogeneity with inferior clinical outcome in human 
DLBCL patients189,260,261, we found that AICDA overexpression in mice was 
associated with increased inter-tumor methylation heterogeneity (Figure 2.12) 
and was linked to more aggressive disease in murine B-cell tumors (Figure 
2.11).  We suggest that AICDA-induced epigenetic heterogeneity increases 
plasticity, thereby allowing cancer cells a greater degree of population diversity 
and enhancing the adaptive capacity of the overall tumor.  Additionally, we 
found further evidence that ABC-DLBCLs, which are more aggressive than 
their GCB-DLBCL counterparts with inferior clinical outcome73, are associated 
with high AICDA expression along with greater epigenetic heterogeneity.  This 
suggests that AICDA may be among the contributing factors to epigenetic 
heterogeneity in ABC-DLBCL. 
 
Previously, the role of AICDA in lymphomagenesis has been linked to its 
mutagenic potential.  Our data suggest additional dimensions to the 
deleterious effect of this protein in DLBCL, via enhanced epigenetic plasticity. 
The epigenetic role of AICDA in neoplastic transformation and cancer 
progression may also reach beyond GC-derived lymphomas.  AICDA can be 
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transcriptionally upregulated in epithelial cells via NFκB signaling following 
cytokine stimulation or exposure to pathogenic factors, such as Helicobacter 
Pylori19.  AICDA has also been implicated in non-lymphoid cancers, including 
melanoma and pancreatic carcinomas262,263.  Such association between 
inflammation, infection, and expression of AICDA may prove to be a missing 
link between chronic inflammation and increased risk of various malignancies. 
 
Aberrant cytosine methylation patterning, along with other epigenetic 
modifications, plays a critical role in the pathogenesis and progression of 
lymphoid malignancies264 and cancer epigenomes have been long 
appreciated to differ from their normal tissue counterparts265,266.  As opposed 
to the genomic DNA sequence, cytosine methylation distribution has great 
plasticity and can be dynamically redistributed in response to environmental 
changes or the influence of transcription regulatory factors97.  One 
consequence of such plasticity is the epigenetic divergence of individual tumor 
cells from each other (Illustration 2.1).  Stochastic intra-tumor epigenetic 
heterogeneity is documented to occur in lymphoid and myeloid malignancies 
and is associated with inferior clinical outcome189,260,261,267,268.  Intra-tumor 
heterogeneity is proposed to increase population fitness in tumors by enabling 
individual cells to derive new epigenetic subclones, providing the tumor with 
greater capacity to adapt and resist therapeutic challenges 269-271.  Intra-tumor 
heterogeneity has also been linked to decoupling of the relationship between 
promoter methylation and gene expression, leading to a more variable 
transcriptional landscape267.  The generation of transcriptionally distinct 
epigenetic subclones, potentially containing regions of variable genomic 
stability, may be detrimental and explain both the prevalence and poor clinical 
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associations of cytosine methylation heterogeneity within lymphoid 
malignancies.  In support of this hypothesis, fitness simulations have shown 
that, even in the absence of change in the mean phenotype, propensity toward 
phenotypic variability itself can substantially increase population fitness within 
a changing environment272.  All mechanisms will need more formal 
examination before the final model of AICDA-mediated epigenetic regulation is 
articulared, but our work indicates for the first time a clear role epigenetic role 
for AICDA in B cell maturation during GC transition and as a driver for cytosine 
methylation heterogeneity. 
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ration 2.1 
	 67 
  
2.14 Materials and methods 
Mouse and Human B Cell Isolation  
Aicda-/- mice were a generous gift from T. Honjo.  WT (BALB/c) mice were 
from The Jackson Laboratory.  All animals were maintained according to the 
guidelines of the Research Animal Resource Center of the Weill Cornell Med- 
ical College, which approved all mouse procedures.  10- to 12-week-old WT or 
Aicda-/- mice were immunized intraperitoneally with NP-CGG ratio 20-25 
(Biosearch Technologies) in alum (1:1) to induce GC formation.  Mice were 
sacrificed at day 10 after immunization, spleens were dissected, and 
mononuclear cells were purified using Histopaque (Sigma) gradient 
centrifugation. Cell suspensions were enriched in B cells by positive selection 
with anti-B220 magnetic microbeads (Miltenyi Biotech).  B cells were 
separated in NB (B220+GL7-FAS-DAPI-) and GCB (B220+GL7+FAS+DAPI-) 
using a BD FACSAria II sorter.  Spleens of VavP-Bcl2 and VavP-Bcl2+Aicda 
mice were dissected, cell suspensions were prepared, and mononuclear cells 
were purified as above. 
Leftover human tonsils were obtained after routine tonsillectomies, performed 
at New York Presbyterian Hospital.  All tissue collection was approved by the 
Weill Cornell Medical College Institutional Review Board.  Tonsils were minced 
and mononuclear cells were isolated using Histopaque density centrifugation. 
NBs for were separated by positive selection using the AUTOMACS system 
(Miltenyi Biotech) after incubation with anti-IgD fluorescein isothiocyanate 
(FITC) (BD Pharmingen) followed by anti-FITC microbeads (Miltenyi Biotec). 
GCBs were separated by positive selection with anti-CD77 (AbD Serotec) 
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followed by mouse anti-IgM, IgG1 isotype (BD Pharmingen), and anti-mouse- 
IgG1 microbeads (Miltenyi Biotec).  
Ex vivo activated B-cell cultures  
Mouse splenic NB were purified by negative selection with anti-CD43 
magnetic beads (Miltenyi Biotec) and were stimulated with 25 µg/ml LPS 
(Sigma Aldrich), 25 ng/ml IL-4 (R & D Systems) and 1 µg/ml anti-CD40 
(eBioscience). One day after culture, cells were infected with EV or AICDA-
expressing retroviral vector pMIG, described previously273.  The cDNA 
encoding mouse AICDA was generated by PCR amplification and was 
subsequently cloned into the multiple cloning site of pMIG274.  Total cultures 
were analyzed after 96 h stimulation and GFP+IgG1+ cells were sorted using 
a BD FACSAria II sorter.  
Flow Cytometry Analysis and Antibodies  
Flow cytometry analysis of mouse NBs and GCBs was performed using the 
following fluorescent-labeled anti-mouse antibodies: APC-conjugated anti- 
B220 (BD Pharmingen), PE-Cy7-conjugated anti-CD95 (BD Pharmingen), 
FITC-conjugated anti-GL7 (BD Pharmingen), and PE-conjugated CXCR4 
(eBioscience).  Cell-cycle analysis was performed using the BrdU Flow Kit (BD 
Pharmingen), and antigen-specific GCBs (NP+GL7+CD95+B220+) was 
detected using PE-conjugated NP (Biosearch Technologies).  Ex vivo 
stimulated B cells were stained with PE-Cy7-conjugated anti-B220 
(eBioscience), PE-conjugated anti-IgD (BD Pharmingen), and APC-conjugated 
anti-IgG1 (BD Pharmingen).  DAPI was used for the exclusion of dead cells.  
Data were acquired on a MACSQuant analyzer (Miltenyi Biotec) and analyzed 
using FlowJo 7.6.4 software (Tree Star).  
Animal models  
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Bone marrow cells from 8-10-week-old BCL2 transgenic animals (VavP-
Bcl2)275 were harvested and transduced with viral supernatants containing 
either EV or AICDA-expressing retroviral vector pMIG.  Two million bone 
marrow cells of each condition were injected into the tail veins of lethally 
irradiated recipient C57BL/6J mice.  All mice were followed until any one of 
several criteria for euthanizing were met, including severe lethargy and more 
than 10% body weight loss in accordance with our Weill Cornell Medicine 
Institutional Animal Care and Use Committee–approved animal protocols.  All 
animals were maintained according to the guidelines of the Research Animal 
Resource Center of Weill Cornell Medicine.  
DLBCL Patient Samples  
Human DLBCL samples were obtained as previously described by Pan et 
al261.  In brief, genomic DNA (gDNA) was extracted from frozen solid tissue 
sections.  The tumor purity of DLBCL samples was above 80-90% based on 
histological observation.  Frozen tissue samples were first digested overnight 
with 0.5 mg ml−1 Proteinase K and 0.625% SDS in 4 ml Nucleic Lysis Buffer 
at 37 °C.  After digestion, 1 ml of saturated NaCl was added to the samples 
and samples were shaken vigorously for 15 s before spun at 2,500 r.p.m. for 
15 min.  Supernatant was transferred to a new tube and mixed with two 
volumes of room temperature 100% ethanol.  DNA was precipitated by 
centrifugation at maximum speed for 30 min, washed twice with 70% ethanol 
and finally dissolved in TE or nuclease-free water overnight at room 
temperature.  
To assess AICDA expression differences between DLBCL subtypes, we 
analyzed 287 newly diagnosed and characterized DLBCL cases, in which 
individuals were treated with R-CHOP (given with curative intent) at the BC 
	 70 
Cancer Agency (Vancouver)276. These studies were approved by the 
Research Ethics Board at The University of British Columbia, British Columbia 
Cancer Agency (REB#H13-01478).  
Enhanced reduced representation bisulfite sequencing (ERRBS)  
To quantify the epigenetic diversity within the different groups, we calculated 
pairwise methylation distance between ERRBS profiles using rectilinear 
Manhattan distance normalized to 1e+06 CpGs for all CpGs that were 
represented between both samples.  The value of the distribution of all 
pairwise distances within a group of samples defines the average methylation 
diversity of that group.  To make no assumptions regarding the distribution of 
these pairwise distances, Wilcoxon rank sum tests were used to compare 
between conditions.  Genomic distribution of CpGs was determined using the 
ChIPseeqerAnnotate module in the ChIPseeqer package277.  Significance of 
genomic distributions of DMCs versus all represented CpGs was assessed 
using Fisher’s exact test. DMC-enriched repeat elements were identified using 
2-fold threshold for DMC fraction relative to all represented CpG fraction and a 
Bonferroni-adjusted binomial test p<0.05.  Association of genes and DMRs 
was performed by identifying RefSeq genes that overlap DMRs within -2kb of 
TSS to transcription end site (TES). 
Murine gDNA was extracted using the Puregene Gentra cell kit (QIAGEN) and 
eluted in TE.  The gDNA quality was assessed using 1% agarose gel to 
assure no shearing. Quality of purified DNA was checked using an Agilent 
2100 Bioanalyzer. 50 ng gDNA was bisulfite converted using the EZ DNA 
Methylation kit (Zymo Research).  Base-pair-resolution DNA methylation 
analysis was performed on gDNA following the ERRBS protocol previously 
described230.  To compare loss of highly methylated CpGs in VavP-Bcl2+Aicda 
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tumors, we performed a Fisher’s Exact Test and classified ‘high methylation’ 
state as CpGs with mean methylation level greater than 70%. Delta mean 
methylation was calculated by subtracting the mean control (e.g. VavP-Bcl2 
tumors, WT GC B cells, AICDA-low DLBCL) methylation value from the mean 
experimental (e.g. VavP-Bcl2+Aicda tumors, Aicda-/- GC B cells, AICDA-high 
DLBCL) methylation value. Delta IQR among replicates were calculated by 
subtracting the IQR among control replicates from the IQR among 
experimental replicates.  PCA was performed on mean-centered data. AICDA-
perturbed CpGs were defined as CpGs with component loading factor greater 
than two standard deviations above mean loading factor.  To quantify the 
degree of intra-sample heterogeneity, we calculated the minimum distance 
from the methylation value of each CpG to [0,1] (i.e., the distance away from 
the closest homogenous unmethylated/methylated state).  Using this metric, 
the maximum intra-sample heterogeneity is 0.5, reflecting a population state 
with half of loci being methylated and the other half being unmethylated.  To 
compare intra-tumor heterogeneity between conditions without assumptions of 
distribution, we performed pairwise Wilcoxon rank sum tests.  Genes over-
representing signature CpGs were identified according to hypergeometric test 
(Benjamini-Hochberg-adjusted P<0.05) using all ERRBS-represented CpGs 
within the gene body (interval from +2kb of TSS to TES). 
RNA sequencing  
Total RNA was extracted from murine tissues or human DLBCL patient 
samples using Trizol (LifeTechnologies) and RNeasy isolation Kit (Qiagen).  
RNA concentration was determined using Qubit (LifeTechnologies) and 
integrity was verified using Agilent 2100 Bioanalyzer (Agilent Technologies).  
Libraries were generated using the TruSeq RNA sample kit (Illumina).  First-
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strand synthesis was performed using random oligos and SuperscriptIII 
(Invitrogen).  After second-strand synthesis, a 200-bp paired-end library was 
prepared following the Illumina paired-end library preparation protocol.  Pair-
end sequencing (PE50) was performed on Illumina HiSeq2000.  RNA 
sequencing results were aligned to mm10 or hg19, respectively, using 
STAR278 and annotated to RefSeq using the Rsubread package279.  DLBCL 
subtype classification was performed using RNAseq profiles as described in 
Cardenas, et al280.  
Real-Time qPCR  
cDNA synthesis from RNA was performed using the Verso cDNA Synthesis kit 
(Thermo Scientific). The expression was detected using the Green FastMix kit 
(Applied Biosystems) on a 7900HT Fast RT-PCR System (Applied Bio- 
systems). Gene expression was normalized to RPL13 using the DDC(t) 
method, and results were represented as fold expression compared to NBs. 
Primer sequences for qPCR 
Used for  Gene  
 
Oligonucleotide (5'-3')  
qPCR Aicda Fwd  GGAGAGATAGTGCCACCTCC  
  
Rev  TCTCAGAAACTCAGCCACGT  
PCR Abcc4 Fwd  GCCCCTAAGCTACCAGCTCT  
  
Rev  GCAGAACAGGGTCTCTCGTC  
 
Cd83 Fwd  ACGCTTGCTCCCTCTTTACA  
  
Rev  GCTCGGGGGAAATTTTACTT  
 
Rassf3 Fwd  ATGAGCCCGGTTTAATCCTC  
  
Rev  ATAGGTACGAAGCGCACCAC  
 
JH4 Fwd  GTCAAGGAACCTCAGTCACCGTCT  
  
Rev  CAGACCTCTCTAGACAGCAACTACC  
 
Sµ Fwd  AATGGATACCTCAGTGGTTTTTAATGGTGGGTTTA  
  
Rev  GCGGCCCGGCTCATTCCAGTTCATTACAG  
V(D)J rearrangement analysis  
PCR products were cleaned-up using the MinElute PCR Purification kit 
(QIAGEN) and subsequently were purified on a gel using the Gel Extraction kit 
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(QIAGEN).  Sequencing libraries were constructed from the purified PCR 
product by using Illumina TruSeq DNA Sample Preparation Kit v2 (Illumina).  
Each sample was tagged with a unique index and sequenced on the Illumina 
MiSeq platform producing 2x151bp paired-end reads.  Paired-end sequence 
reads were mapped against the IGH mouse reference database available from 
the IMGT website (reference: imgt.org) using a modified nucleotide blast 
search.  Sequences without a match in Ig heavy chain V regions were filtered 
out and reads with a corresponding match to a VH region were counted for the 
number of each unique rearrangement.  We then performed statistical analysis 
to see whether there was a difference in the selection of Ig rearrangements 
between the samples by comparing the clonality.  As described in Jiang et 
al.281, clonality was measured using an adjusted measure of Shannon’s 
entropy of the distribution of VH region selection counts.  This gives some 
indication as to the shape of the distribution of VH regions in each sample and 
is influenced by the number of reads mapped and how clonal each sample is.  
The lower the entropy is, the more skewed towards a single VH region the 
distribution is (i.e., the more clonal it is).  
Immunoblotting  
Total cell extracts were prepared after treatment with lysis buffer (10 mM Tris 
[pH 7.4], 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 1% Triton X-100, 
0.1% SDS, and 1mM EDTA) supplemented with PMSF (Sigma) and a 
protease inhibitor cocktail (Roche).  Lysates were subjected to SDS-PAGE, 
transferred to a polyvinylidene fluoride membrane (Bio-Rad Laboratories), and 
blotted with anti-AID (L7E7, Cell Signaling Technology) or anti-actin (A5441, 
Sigma).  Signals were detected with horseradish-peroxidase-
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secondary antibodies (Santa Cruz Biotechnology) using the ECL system 
(Thermo Scientific).  
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CHAPTER THREE: 
EZH2 TRANSCRIPTIONAL REPRESSION IN GC REACTION AND GC-
DERIVED LYMPHOMAGENESIS*	
 
3.1 EZH2 activity is key to germinal center formation  
Previous studies have identified increased expression of EZH2 in GC B cells 
and demonstrated the importance of EZH2 to the growth of lymphoma 
cells47,92-94.  However, the role and requirement for EZH2 and its mutant 
alleles in the formation of GCs and pathogenesis of B cell lymphomas is not 
well explored.   Additionally, the mechanism by which EZH2 contributes to 
transformation, beyond association with global cellular abundance of 
H3K27me3, is unknown.  To explore the function of WT and mutant EZH2 in 
mature B cells and lymphomas, we attempted to generate a conditional   
EZH2-/- mouse model.  EZH2 deletion is lethal in early embryonic 
development48, and its inducible knockout in early hematopoietic cells perturbs 
lymphoid differentiation at the pre-B cell stage50.  We therefore crossed 																																																								
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conditional Ezh2-/- mice with the Cγ1cre strain, which expresses cre 
recombinase in GC B cells282.  Upon reaching immunological maturity, Ezh2fl/fl, 
Ezh2-/-, and WT control mice were injected with T cell-dependent antigen 
sheep red blood cells (SRBC) to induce GC formation and sacrificed 10 days 
later, at which time the GC reaction is at its peak.  EZH2 loss resulted in a 
marked reduction in the number of splenic GC (GL7+/FAS+/B220+) B cells 
(Figure 3.1A).  Immunohistochemical analysis using peanut agglutinin (a GC 
B cell marker) revealed a reduction in the number (p < 0.0001) and size (p = 
0.001) of GCs in Ezh2-/- versus Ezh2+/+ mice, whereas there was no change in 
GCs in Ezh2fl/fl mice (Figure 3.1B).  We then immunized a cohort of C57BL6 
mice with SRBC followed by once daily treatment with 150 mg/kg/day 
GSK503, a specific EZH2 methyltransferase inhibitor, or vehicle.  GSK503, but 
not vehicle, prevented the formation of GC after SRBC or NP-KLH 
immunization, phenocopying the Ezh2 null phenotype.  GSK503 treatment led 
to reduced numbers of GC B cells by flow cytometry (Figure 3.1C) and 
reduced number and volume of GCs by immunohistochemistry (Figure 3.1D).  
Collectively, these data demonstrate that EZH2 is required for the formation of 
GCs and that this function is dependent on its histone methyltransferase 
activity. 
 
Given that EZH2 was essential for development of GC B cells, we surmised 
that gain-of-function EZH2 mutants might reinforce these actions, with 
implications for lymphomagenesis.  To address this point, we generated mice 
conditionally expressing the Ezh2Y641N lymphoma in GC B cells, using a Cγ1-
cre background.  We observed a 3-fold increase in the abundance of 
H3K27me3 in sorted GC B cells from Ezh2Y641N versus nonrecombined mice 
	 77 
(p < 0.005; Figure 3.1E), analogous to what is observed in mutant EZH2 
DLBCL cell lines88,93.  After immunization, Ezh2Y641N mice displayed greatly 
increased numbers of GL7+/FAS+/ B220+ GC B cells (p < 0.001; Figure 3.1F) 
and increased number and size of GCs (p < 0.0005; Figure 3.1G), while cre-
negative Ezh2fl/fl animals showed no such effects.  These data demonstrate 
that Y641 mutation reinforces the GC phenotype-driving function of wild-type 
EZH2, resulting in an expansion of these proliferative and mutagenic cells.  
However, Ezh2Y641N knockin mice did not develop B cell lymphomas (data not 
shown).  
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Figure 3.1 
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3.2 EZH2 mediates differentiation blockade in DLBCL cells 
GCB-DLBCLs exhibit differentiation blockade, locking them into the GC 
phenotype283.  Given that gain-of-function mutants induce an expansion in the 
population of GC B cells, we postulated that EZH2 might play a critical role in 
suppressing differentiation.  To test this, we expressed wild-type EZH2 and 
EZH2Y641 in murine BCL1, a cell line originating from a spontaneous murine 
lymphoproliferative disease that exhibits clonal somatic hypermutation and has 
been used to model GC B cell biology284.  BCL1 cells were transduced with 
GFP-expressing retrovirus harboring FLAG-tagged Ezh2Y641N, Ezh2Y641F, or 
WT Ezh2 and subsequent RNAseq was performed.  Comparing RNAseq gene 
expression profiles in transduced BCL1 cells, we observed that EZH2Y641N and 
EZH2Y641F increased repression of genes that are normally expressed upon 
terminal differentiation into plasma and memory cells when compared to 
EZH2-WT-expressing cells (gene set enrichment analysis [GSEA] false 
discovery rate [FDR] q = 0.009; Figure 3.2A).  We then induced differentiation 
in BCL1 cells using interleukin-2 (IL-2) and IL-5, which typically drive BCL1 
cells toward a partial plasma cell phenotype accompanied by proliferation 
arrest284.  Expression of EZH2Y641N or EZH2Y641F but not WT-EZH2 
significantly impaired cytokine-induced proliferation arrest (t-test p < 0.05; 
Figure 3.2B) and more profoundly suppressed activation of Prdm1, a key 
plasma cell differentiation gene (t-test p < 0.01; Figure 3.2C). 
  
Based on these data, we next examined whether EZH2 inhibition by GSK343 
could induce differentiation in human DLBCL cells.  In GCB-type DLBCL cell 
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lines (two mutant and one WT), EZH2 inhibitor treatment induced functional 
evidence of differentiation manifested by increased light chain and 
immunoglobulin production (Figure 3.2D) and morphologic changes 
consistent with plasma cell differentiation (Figure 3.2E).  Gene expression 
analysis by quantitative PCR revealed upregulation of differentiation-related 
genes, including PRDM1, IRF4, and syndecan CD138, with greater effect 
generally noted in EZH2 mutant DLBCL cells (p < 0.05; Figure 3.2F).  
Analysis of RNAseq expression profiles induced by GSK343 found strong 
enrichment in gene sets involved in exit from the GC reaction, including genes 
induced by CD40, IRF4, IL10, and NFκB, and, notably, the ABC-DLBCL 
signature (which consists of activation of these post-GC genes), as well as 
genes involved in apoptosis and immune responses (Figure 3.2G).  Memory 
and plasma cell differentiation genes were among genes preferentially 
repressed in GCB-type DLBCL patients with EZH2 mutations as compared to 
GCB-DLBCL patients with WT EZH2 (FDR q < 0.001; Figure 3.2H).  
Collectively, these data suggest that EZH2 maintains the GC phenotype by 
suppressing transcriptional programs required for exiting the GC reaction and 
terminal differentiation. Mutant EZH2 augments these same functions by 
reinforcing repression of B cell differentiation genes. 
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Figure 3.2 
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3.3 Mutant EZH2 aberrantly repressed gene via increased promoter 
H3K27me3 
In order to gain insight into how mutant EZH2 might reinforce or alter normal 
EZH2-dependent transcriptional programs, we performed H3K27me3 ChIPseq 
in BCL1 cells after transduction with EZH2Y641N, EZH2Y641F, WT EZH2, or 
vector and determined how gene expression in these cells responded to EZH2 
inhibitors.  Cells transduced with either EZH2Y641N or EZH2Y641F showed a 
marked increase in the abundance of H3K27me3 at gene promoters 
compared to EZH2 WT-transduced cells (Wilcoxon p < 2 x 10-16 for both 
mutants; Figure 3.3A), and genes with abundant H3K27me3 were generally 
repressed (p < 2 x 10-16; data not shown).  In addition, loci displaying 
increased H3K27me3 were more potently induced upon exposure of the 
BCL1- EZH2Y641N/EZH2Y641F cells to GSK343 than EZH2 WT cells (Wilcoxon p 
< 5 x 10-11 for EZH2Y641N and EZH2Y641F; Figure 3.3B).  Hence, mutant EZH2 
appears to function at least in part by increasing the burden of epigenetic 
repressive marks at gene promoters. 
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Figure 3.3 
 
3.4.  Identification of H3K27me3 enrichment from ChIPseq experiments 
Although unbiased genomic surveys of H3K27me3 can be made using 
ChIPseq, identification of H3K27me3-enriched loci can be problematic.  
Repressive histone modifications, such as H3K27me3, typically cover long, 
continuous regions and form heavily condensed heterochromatin285,286.  Unlike 
transcription factors and histone modifications that span a small number of 
nucleosomes and show narrow and strong ChIPseq enrichment, the broad 
and low-level enrichment of H3K27me3 cannot be detected reliably by 
ChIPseq peak callers, such as MACS which is designed to detect in narrow 
windows287.   
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In order to identify regions of H3K27me3 enrichment in NB and GCB, we first 
quantified H3K27me3 occupancy into read counts genome-wide in 1kb bins 
and transformed the counts into z-scores (Figure 3.4A).  To remove single 
outlier bins with exceptionally high H3K27me3 ChIPseq read counts located 
adjacent to bins with read counts near or below the genome-wide mean, we fit 
a cubic spline to the z-scores within a sliding window of 1MB, defining the loci 
corresponding to spline-fitted z-score values above 1 as putative “broad 
domains” (Figure 3.4B).  This approach identified broad regions of enrichment 
that showed good correspondence with observed H3K27me3 ChIPseq read 
density (Figure 3.4C).  To validate that these called regions of H3K27me3 
enrichment were associated with transcriptional repression, we compared the 
expression of genes in human GCB with and without H3K27me3 broad 
domain enrichment within their promoters (±2kb TSS).  We found that genes 
not associated with broad domains exhibited a range of expression values, but 
genes with broad domains overlapping their promoters were silenced or 
restricted to low expression values (Figure 3.4D). 
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Figure 3.4 
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3.5 EZH2 is linked to de novo formation of GCB-specific bivalent genes 
that are implicated in differentiation 
To assess the transcriptional impact of mutant EZH2 upon the GCB-specific 
EZH2 targets, we identified genes associated with promoter H3K27me3 broad 
domains and are downregulated in GCB compared to NB cells.  We found that 
these GCB cell-specific H3K27me3 targets (n=510) were further repressed in 
BCL1 cell transduced with EZH2Y641F or EZH2Y641N than in their BCL1- WT 
EZH2 counterparts (FDR q < 0.001; Figure 3.5A), suggesting that mutant 
EZH2 exaggerates the epigenetic silencing of normal GC B cell EZH2 targets.  
 
In stem cells, a subset of genes that are H3K27 trimethylated by EZH2 are 
also marked by the activating chromatin modification H3K4me3.  These so-
called ‘‘bivalent (H3K4me3/H3K27me3) domains’’ are believed to represent a 
mechanism for poising key lineage transcription factors so that they can be 
either activated or repressed during subsequent differentiation225.  We 
examined H3K27me3 and H3K4me3 distribution in purified primary human NB 
cells and GC B cells by ChIPseq. Notably, even though GC B cells are mature, 
committed cells (i.e., in contrast to stem cells), we find that they gain 1,026 
new bivalent domains at promoters that are not found in NB cells (Figure 
3.5B).  Of these 910 (88%), bivalent promoters originate from H3K4me3-only 
promoters in NB cells (Figure 3.5B), indicating that most bivalent loci in GC B 
cells occur due to acquisition of H3K27me3, concordant with upregulation of 
EZH2 in these cells.  ChIPseq profiles from seven human GCB-DLBCL cell 
lines showed that these bivalent promoters were preferentially bound by EZH2 
(Anova p < 1 x 10-16; Figure 3.5C).  In primary human GC B cells, bivalent 
genes were expressed at lower levels than loci with H3K4me3 alone but at 
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higher levels than genes marked only by H3K27me3 (Wilcoxon p < 1 x 10-300; 
Figure 3.5D), consistent with the proposed poised nature of bivalent genes 
and observations of minimal expression in stem cells225.  GC B cell bivalent 
genes were highly enriched in gene sets associated with termination of the GC 
reaction, such as IRF4-induced, ABC-DLBCL, memory cell upregulated genes, 
as well as other GC B cell relevant genes, such as negative regulation of cell 
cycle (Figure 3.5E). The key regulatory transcription factors IRF4 and PRDM1 
were among the GC B cell-specific bivalent genes, consistent with the notion 
that these genes are marked for dynamic activation upon exit from the GC 
reaction (Figure 3.5F) and that bivalent marks at this stage of B cell 
maturation function to transiently suppress terminal differentiation.  
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Figure 3.5 
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We wondered whether somatic mutation of EZH2 might “lock” these bivalent 
promoters into a more repressed configuration, perhaps helping to explain the 
irreversible differentiation blockade induced by mutant EZH2.  Indeed, we 
observed that GC B cell bivalent genes were even more highly repressed in 
murine BCL1 cells transduced with EZH2Y641N and EZH2Y641F than in WT 
EZH2-transduced cells (FDR q < 0.001; Figure 3.6A).  GC B cell bivalent 
domain genes were also significantly more repressed in human GCB-DLBCL 
patients with EZH2 somatic mutations compared to GCB-DLBCL with WT 
EZH2 (FDR q < 0.001; Figure 3.6B).  GC B cell bivalent genes involved in GC 
B cell differentiation, such as IRF4-induced genes, CD40-induced genes, and 
plasma/ memory cell genes, were especially enriched among genes 
differentially expressed in mutant EZH2 DLBCL patients versus GCB-DLBCL 
specimens with wild-type EZH2 (Figure 3.6C).  To confirm that bivalent marks 
are indeed occurring at the same chromatin regions within GC- derived 
DLBCL cells, we performed ChIP re-ChIP assays.  The key regulatory 
transcription factors necessary for GC exit, IRF4, and PRDM1, as well as the 
proliferation checkpoint gene promoter CDKN1B, all shown to be putative 
GCB bivalent genes by our ChIPseq experiments, were confirmed to be 
significantly co-occupied by H3K27me3 and H3K4me3 marks (Figure 3.6D).  
In contrast, HOXA7 (which is silenced in mature B cells) was exclusively 
H3K27 trimethylated and BCL6 (which is highly expressed in GC B cells) was 
almost exclusively H3K4 trimethylated.  Collectively, these data suggest that, 
in normal GC B cell development, EZH2 reversibly suppresses terminal 
differentiation by forming or maintaining bivalent domains at specific loci that 
are also marked by H3K4me3, in addition to epigenetically silencing other 
genes through pure H3K27me3.  In B cell lymphomas, mutant EZH2 
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reinforces silencing of these genes, perhaps by increasing the frequency with 
which these genes are H3K27 methylated among tumor cells or by more 
subtle stoichiometric effects, tipping the balance of H3K27 toward 
trimethylation and away from demethylation.  
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Figure 3.6 
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3.6 EZH2 cooperates with BCL2 to generate GC-derived lymphomas 
We next investigated whether mutant EZH2 might cooperate with other GC B 
cell lymphoma oncoproteins, such as BCL2, which is frequently translocated in 
patients with EZH2Y641 mutations84.  We transduced bone marrow of VavP-
Bcl2 mice with retrovirus expressing GFP and encoding WT EZH2, EZH2Y641F, 
or GFP alone and transplanted them into lethally irradiated cohorts of ten 
recipients each (Figure 3.7A).  Animals were immunized with SRBC every 
four weeks to ensure continuous formation of GCs.  Macroscopic examination 
of spleens showed marked splenomegaly in EZH2Y641F versus EZH2 WT or 
empty vector (Figure 3.7B).  Immunoblot analysis of splenic extracts showed 
similar levels of expression of EZH2 in the EZH2 WT and EZH2Y641F mice 
(Figure 3.7C).  By contrast, H3K27me3 abundance was only elevated in 
splenocytes from EZH2Y641F mice, whereas H3K27me3 levels in EZH2 WT 
mice were similar to controls (Figure 3.7C).  The livers of EZH2Y641F but not 
EZH2 WT mice were also significantly enlarged versus vector control (Figure 
3.7D).  All EV and WT EZH2 mice displayed evidence of follicular hyperplasia, 
as expected in Bcl2 transgenic mice (Figure 3.7E).  However, examination of 
spleens in EZH2Y641F/Bcl2 mice revealed disruption of splenic architecture by 
neoplastic-appearing B220+ B cells (Figure 3.7E).  
 
Given that BCL2 and EZH2 can cooperate in lymphomagenesis, we 
hypothesized that BH3 mimetic drugs that block BCL2 function, such as 
Obatoclax and ABT737, might enhance the activity of EZH2 inhibitors. We 
exposed a panel of GCB-DLBCL cells to increasing concentrations of 
GSK343, in combination with ABT737 or Obatoclax.  In almost every cell line 
tested, the concentration of GSK343 or GSK503 required to yield 90% growth 
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inhibition was reduced when cells were concomitantly treated with BH3 
mimetics (Figure 3.7F).  In order to determine the impact of EZH2 inhibitor 
combinatorial therapy in a preclinical model, we evaluated the action of 
GSK503 and Obatoclax alone or in combination in mice bearing human 
DLBCL cell line (SUDHL4 and SUDHL6) xenografts.  Although both GSK503 
and Obatoclax inhibited tumor growth alone, the combination of these 
inhibitors again more potently and significantly suppressed tumor xenograft 
growth (Figure 3.7G).  EZH2 mutants therefore enable, accelerate, and 
maintain malignant transformation of GC B cells in cooperation with BCL2.  
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Figure 3.7 
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3.7 EZH2 targeted therapy preferentially affects GCB-DLBCL, but not 
ABC-DLBCL 
EZH2 gain-of-function somatic mutations are restricted to GCB- type 
DLBCLs288.  Moreover, whereas EZH2 is a critical mediator of the GC B cell 
phenotype, which is reflected by the phenotype of GCB-DLBCL, it also 
represses genes and pathways that drive the phenotype of ABC-DLBCLs 
(e.g., IRF4 and NFκB pathway genes).  We questioned whether these GCB-
specific functions would translate to a specific role for EZH2 in the 
pathogenesis and therapeutic targeting of GCB versus ABC subtypes of 
DLBCL.  Along these lines, we noted that GCB EZH2 target genes were 
significantly more repressed in GCB- than in ABC-DLBCLs, although even 
more significantly repressed when comparing ABC versus mutant EZH2 
DLBCLs (Figure 3.8A).  Gene set enrichment analysis revealed that EZH2 
target genes, including GCB bivalent genes were overrepresented among 
genes upregulated in ABC versus GCB DLBCLs (FDR q < 0.001; Figure 
3.8B), with enrichment scores even higher when comparing ABC versus 
mutant EZH2 DLBCLs (FDR q < 0.001; Figure 3.8C).  Hence, EZH2 target 
genes, including those with bivalent marks at the GC stage of development, 
are expressed at relatively higher levels in ABC-DLBCL cells, suggesting that 
EZH2 does not play a key role in their regulation in this form of lymphoma 
associated with the transformation of a postgerminal center B cell.  
 
If EZH2 is not critical for the suppression of bivalent genes that drive 
proliferation once a cell exits the GC, then the biological effects of EZH2 
inhibition would be predicted to be significantly different for ABC- versus GCB-
DLBCL cells and ABC-DLBCL cells might be predicted to be relatively 
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insensitive to EZH2 inhibitors.  Therefore, we treated a panel of ABC- and 
GCB-DLBCL cell lines with increasing concentrations of GSK343.  Strikingly, 
the drug concentrations required to inhibit 50% of growth (GI50) for GCB-
DLBCL cell lines were in the 0.5–20 mM range, while, for ABC-DLBCL cells, 
no significant inhibition of cell growth was observed (t-test p = 0.0004; Figure 
3.8D).  Exposure of EZH2 WT GCB-DLBCL cells to a fixed dose of 10 mM 
GSK343 led to 30%–75% reduction in viable cell number, while EZH2 mutant 
GCB-DLBCL cells were inhibited 50%–99%, suggesting a trend toward 
increased sensitivity.  By contrast, this dose of drug led to no killing of ABC 
lymphoma cells (t-test p = 0.0001 versus GCB; Figure 3.8E).  EZH2 inhibitors 
completely demethylated H3K27me3 in ABC-DLBCL cells, indicating that 
resistance is biological and not due to failure of the drug to inhibit its target 
(Figure 3.8F).  Collectively, these data suggest that EZH2 inhibitors may be 
useful for GCB DLBCL either with or without EZH2 mutations but are likely to 
be ineffective for ABC-type DLBCL.  
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Figure 3.8 
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3.8 EZH2 is required for BCL6 to drive GC hyperplasia 
The canonical mechanism by which EZH2 represses transcription is through 
recruitment of PRC1 complexes.  However, GC centroblasts lack canonical 
core PRC1 components such as PCGF2/MEL18 and PCGF4/BMI152, raising 
the question of how EZH2 coordinates repression in this context.  The critical 
dependency of GC B cells on EZH2 thus provides an opportunity to explore 
key determinants of its noncanonical and context-specific mechanisms of 
action.  Various other modes of action of EZH2 have been proposed, including 
potential cooperation with sequence-specific transcription factors205,289.  Along 
these lines, the parallels between EZH2 and BCL6 are especially 
intriguing290,291 and prompted us to explore whether and how these proteins 
might cooperate to control transcriptional repression and mediate the GC 
phenotype. 
 
The similar effects of BCL6 and EZH2 on the GC phenotype prompted us to 
evaluate whether BCL6 and EZH2 cooperate in the development of GCs.  To 
explore this question, we crossed conditional Ezh2fl/fl knockout mice50 with the 
Cγ1-cre strain, which expresses CRE recombinase in established GC B 
cells282.  These animals were crossed to IµBcl6 mice, which maintain 
constitutive BCL6 expression in GC B cells290.  Ezh2fl/fl;Cγ1-cre, IµBcl6, 
Ezh2fl/fl;Cγ1-cre;IµBcl6, and Ezh2fl/fl control mice were immunized with SRBC 
to induce GC formation and sacrificed 10 days later, at which time the GC 
reaction is at its peak.  Notably, deletion of Ezh2 from GC B cells not only 
abrogated the BCL6-induced hyperplastic phenotype but also resulted in 
profound reduction in GC B cells (FAS+/GL7+/B220+, t-test p < 0.001; Figure 
3.9A and B).  Immunohistochemical analysis using GC B cell marker peanut 
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agglutinin further revealed a reduction in the number and size of GCs in 
Ezh2fl/fl;Cγ1-cre;IµBcl6 versus Ezh2fl/fl controls (t-test p < 0.05; Figure 3.9C).  
To determine if the requirement for EZH2 is dependent on its enzymatic 
function, we next immunized IµBcl6 mice with SRBC followed by daily 
treatment for 9 days with the EZH2 inhibitor GSK503 or vehicle.  We found 
that GSK503 prevented GC hyperplasia in IµBcl6 mice, manifesting fewer GC 
B cells by flow cytometry (t-test p < 0.001; Figure 3.9D) and reduced number 
and volume of GCs by immunohistochemistry (t-test p < 0.001; Figure 3.9E).  
Collectively, these data show that constitutive expression of BCL6 is unable to 
drive GC hyperplasia in the absence of EZH2 protein or its catalytic activity.  
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Figure 3.9 
 
3.9 BCL6 is required for mutant EZH2 to drive GC hyperplasia 
We performed the reciprocal experiment to determine whether BCL6 is 
required for hyperactive mutant EZH2Y641 to drive lymphoid hyperplasia. 
Because Bcl6 constitutive knockout has a complex and lethal phenotype292, 
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we first generated conditional Bcl6fl/fl;Cγ1-cre mice.  As expected, conditional 
deletion of Bcl6 resulted in profound reduction in GC B cells, underlining that 
wild-type (WT) EZH2 alone is not sufficient to drive GC formation (Figure 
3.10A, B, C).  To determine whether BCL6 was also required to support the 
function of hyperactive mutant EZH2Y641, we generated an additional 
conditional allele, Ezh2(Y641F)fl, that expresses Ezh2Y641F from the 
endogenous Ezh2 locus when activated by CRE.  We assessed the GC 
reaction in the offspring of Bcl6 conditional KO mice crossed with 
Ezh2(Y641F)fl/WT;Cγ1-cre strain.  Bcl6fl/fl;Ezh2(Y641F)fl/WT;Cγ1-cre mice failed 
not only to develop EZH2 driven GC hyperplasia, but also exhibited profound 
reduction of GC B cells (t-test p < 0.001 versus mutant EZH2 and p < 0.05 
versus WT EZH2; Figure 3.10A and B).  We also found significant reduction 
in the number and size of GCs as shown by immunohistochemistry (t-test p < 
0.001; Figure 3.10C). 
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Figure 3.10 
 
3.10 EZH2 and BCL6/BCOR complexes are both required for repression 
of key de novo GC B cell bivalent promoters 
This data suggest a functional dependency between EZH2 and BCL6.  EZH2 
mediates its effects in GC B cells in part through de novo formation of bivalent 
promoters.  BCL6 represses promoters mainly by recruiting the co-repressor 
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protein BCOR41.  To explore potential mechanistic links between EZH2 and 
BCL6, we examined the genomic distribution of H3K27me3, H3K4me3, BCL6, 
and BCOR in purified primary human NB cells and GC B cells using ChIPseq 
data41.  We observed significant overlap of GC de novo bivalent promoters 
with BCL6 and BCOR (hypergeometric test, p = 2.9 x 10-20; Figure 3.11A).  In 
contrast, BCL6 and BCOR were excluded from monovalent H3K27me3 genes 
(depletion p < 1 x 10-76; Figure 3.11B).  BCL6/BCOR-occupied GC de novo 
bivalent genes were significantly enriched for pathways involved in GC exit 
and terminal differentiation, including genes induced by IRF4 and T cell 
cytokines, genes highly expressed in ABC-DLBCL signature compared with 
GCB-DLBCL (which includes GC exit genes), and genes associated with 
immune responses (Figure 3.11C).  Among BCL6-BCOR-occupied de novo 
bivalent genes were key proliferation checkpoint (CDKN1A, CDKN1B) and B 
cell differentiation (PRDM1, IRF4) genes (as exemplified in Figure 3.11D and 
E).  Bivalent genes without BCL6/BCOR complexes were not preferentially 
linked to these pathways.  We next compared RNAseq gene expression 
profiles of NB versus GC B cells and found that de novo bivalent genes bound 
by BCL6 and BCOR at their promoters are significantly more repressed in GC 
B compared with NB cells (GSEA FDR, q < 0.001; Figure 3.11F).  To 
determine whether these BCL6-BCOR-bound de novo bivalent genes were 
actively repressed by EZH2 and BCL6, we examined RNAseq profiles of GC-
derived DLBCL cell lines treated with an EZH2 inhibitor or a BCL6 inhibitor 
that disrupts BCL6-BCOR interaction; or EZH2 small hairpin RNAs (shRNAs) 
or BCL6 small interfering RNAs (siRNAs)41.  In all cases, we observed 
significant de-repression of BCL6-BCOR de novo bivalent genes.  In contrast, 
de novo bivalent genes lacking BCL6/BCOR were only de-repressed by EZH2 
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shRNA or inhibitors (Figure 3.11G).  These data suggest functional 
cooperation between EZH2 and BCL6, specifically at genes where BCL6 
recruits BCOR, since EZH2 alone or BCL6 alone is not sufficient to maintain 
repression of these bivalent genes.  
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Figure 3.11 
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Transcriptional repression of H3K27me3-marked chromatin is mediated by 
PRC1 complexes.  However, we found that genes for canonical PRC1 
components BMI1 (PCGF4), PHC1, and PHC3 are repressed and 
downregulated in GC B cells compared with NB cells (Figure 3.12A).  The 
canonical PRC1 component PCGF2 (MEL18) was absent in both GC B and 
NB cells (data not shown).  However, BCOR forms an alternative 
noncanonical complex with certain PRC1 subunits216,293.  Noncanonical PRC1 
genes BCOR, PCGF1, KDM2B, SKP1, and USP7 are upregulated in GC B 
cells, similar to PRC2 (Figure 3.12A).  BMI1 downregulation and BCOR 
upregulation in GC B cells were confirmed by RT-qPCR (Figure 3.12B).  
Immunoblot analysis likewise revealed that GC B cells express higher protein 
levels of BCOR, KDM2B, and PCGF1 than NB cells (Figure 3.12C).  
Remarkably, the core canonical PRC1 component BMI1 is among the de novo 
bivalent genes bound and repressed by BCL6-BCOR complexes (Figure 
3.12D).  The promoter of PCGF2, on the other hand, is marked by only 
H3K27me3 in both GCB and NB cells, suggesting it is highly repressed 
(Figure 3.12D).  Taken together, these data indicate that the noncanonical 
PRC1-BCOR complex may represent the dominant PRC1 in GC B cells.  
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Figure 3.12 
 
3.11 Mutant EZH2 fails to induce GC hyperplasia in absence of 
BCL6/BCOR 
The above data suggest that BCOR, like BCL6, may be required for the 
transcriptional and biological effects of EZH2.  Thus, to determine whether 
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BCOR is required for GC formation, we used a conditional Bcor allele, Bcorfl 
together with the Cγ1-cre allele.  Bcorfl/Y;Cγ1-cre mice failed to form GCs after 
immunization, similar to the case of Ezh2 or Bcl6 deletion (Fiugre 3.13A).  To 
evaluate if mutant EZH2 can drive GC formation or hyperplasia in the absence 
of BCOR, we performed immunization experiments in mice bred for 
simultaneous conditional knockout of Bcor and conditional knockin of 
Ezh2(Y641F)fl/WT with the Cγ1-cre allele.  Bcor deletion in 
Bcorfl/Y;Ezh2(Y641F)fl/WT;Cγ1-cre mice resulted in marked depletion in the 
number of GC B cells (t-test p < 0.001; Figure 3.13B) and significant reduction 
in the number and volume of GCs by immunohistochemistry (t-test p < 0.001; 
Figure 3.13C) 
 
These data suggest that BCL6 and BCOR are each required for the actions of 
EZH2 in established GC B cells, but do not address whether it is the 
interaction between BCL6 and BCOR that mediates this effect.  To address 
this point, we used a Bcl6 allele that encodes a mutant BCL6 protein unable to 
bind to BCOR (Bcl6BTBmut)43.  As previously reported, homozygous Bcl6BTBmut 
mice were unable to form GCs (Figure 3.13D). Bcl6BTBmut homozygous mice 
crossed with Ezh2(Y641F)fl/WT;Cγ1-cre rescued the GC hyperplasia phenotype 
and again abrogated GC formation, as shown by flow cytometry (t-test p < 
0.001; Figure 3.13E) and immunohistochemistry (t-test p < 0.001; Figure 
3.13F).  Collectively, these results demonstrate that WT and gain-of-function 
mutant EZH2 require a functional BCL6-BCOR complex to drive formation of 
GCs and GC hyperplasia, respectively.  
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Figure 3.13 
 
3.12 PRC1-BCOR complex requires both PRC2 and BCL6 for stable 
association and repression of bivalent promoters 
We next evaluated the mechanism through which EZH2, BCL6, and BCOR 
cooperate to mediate the GC phenotype. First, we examined whether BCL6 
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could interact with EZH2.  Using sequential ChIP (ChIP re-ChIP), we 
evaluated whether these proteins were bound to the same loci and found that 
EZH2 is co-recruited at the same bivalent promoters as BCOR and BCL6 as 
shown for the CDKN1B and PRDM1 loci (Figure 3.14A).  However, we were 
unable to detect any interaction either with endogenous or transfected proteins 
(data not shown).  Hence, BCL6-BCOR and PRC2 complexes co-localize on 
chromatin without direct BCL6-EZH2 contact.  
 
To determine whether PRC2 and BCL6-BCOR functionally cooperate on 
chromatin, we treated GC-derived DLBCL cells with the EZH2 inhibitor 
GSK343 or the inactive compound GSK669 and then evaluated recruitment of 
PRC2 components EZH2, EED, and SUZ12; PRC1-BCOR complex 
components BCOR, RING1B, KDM2B, and PCGF1; BCL6; and the PRC2 
histone mark H3K27me3, and the RING1B mark H2AK119ub.  We performed 
qChIP for these proteins in four independent GC-derived DLBCL cell lines at 
six key bivalent promoters (CDKN1B, PRDM1, IRF4, CDKN1A, ARID3A, and 
ARID3B), as well as a negative control region.  EZH2 inhibitor caused a 
significant reduction in both recruitment of PRC2 and BCOR complex 
components, along with concordant loss of H3K27me3 and H2AK119ub 
(Figure 3.14B).  In contrast, BCL6 binding was unaffected.  This suggests 
that, even though EZH2 does not directly interact with the PRC1-BCOR 
complex, stable association of PRC1-BCOR complex with chromatin still 
requires PRC2 activity.  BCL6 occupancy alone is not sufficient to maintain 
maximal PRC1-BCOR recruitment or transcriptional repression of these 
genes, and BCL6 recruitment does not require H3K27me3.  In reciprocal 
experiments, we treated the same cell lines with FX1 to block the interaction 
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between BCL6 and BCOR.  In this case, qChIP revealed loss of PRC1-BCOR 
complex recruitment with no effect on PRC2 occupancy (Figure 3.14C).  We 
observed depletion of both H2AK119ub and H3K27me3, consistent with loss 
of BCOR complex as well as impairment of PRC2 function.  Collectively, these 
data suggest a model whereby BCL6 and EZH2 must cooperate to mediate 
the stable recruitment of the noncanonical PRC1-BCOR complex to bivalent 
promoters in GC B cells. Neither BCL6 nor PRC2 alone are sufficient to 
optimally tether this complex or fully repress expression of these target genes.  
Figure 3.14 
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3.13 CBX8-mediated recruitment of BCOR complex to H3K27me3-marked 
bivalent genes is required for EZH2 function 
BCOR recruitment occurs through direct binding of BCOR to the BCL6 BTB 
domain294-296.  However, it is not known how BCOR is recruited to bivalent 
promoter regions through PRC2.  Canonical PRC1 complexes contain 
chromobox homolog (CBX) histone reader proteins that bind to H3K27me3.  
Hence, we wondered whether CBX proteins might also mediate the PRC2-
dependent recruitment of BCOR complex to bivalent promoters in the GC B 
cell context.  We examined RNAseq gene expression profiles to identify CBX 
family proteins potentially relevant to the GC B cell context (Figure 3.15A).  
Among these, CBX8 was the most differentially upregulated CBX family 
member in GC B cells.  We confirmed CBX8 upregulation in purified GC B 
cells and NB cells using qPCR and immunoblots (Figure 3.15B and C).  
To determine whether CBX8 might form part of the PRC1-BCOR complex, we 
performed BCOR tandem affinity purifications followed by mass spectrometry 
in HEK293 cells and identified CBX8 as a co-purifying protein (data not 
shown).  PCGF1 was also reported enriched in CBX8 purifications in HeLa 
cells297 and differentiating embryonic stem cells298, and CBX8 was also 
associated to a KDM2B-BCOR complex299.  To confirm these results, we 
developed an insect cell reconstitution system for BCOR complexes and 
showed that CBX8 can be incorporated into BCOR complex and 
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immunoprecipitated with BCOR complex components (Figure 3.15D).  A 
previously described co-structure of CBX7 and RING1B and associated 
mutational analysis300 allowed us to identify residues that might inhibit the 
CBX8-RING1B interaction.  Mutation of these residues on RING1B (Y262A) or 
CBX8 (I375D) resulted in failure to incorporate CBX8 into the BCOR complex 
(Figure 3.15D).  To further investigate whether CBX8 associates with BCOR 
in GC B cells, we performed co-immunoprecipitation experiments for the 
endogenous CBX8 and BCOR proteins in two DLBCL cell lines.  CBX8 
antibody enriched for BCOR, as did the reciprocal experiment with BCOR and 
CBX8 immunoblot (Figurer 3.15E).  Most importantly, we confirmed 
endogenous CBX8 association with BCOR in purified GC B cells from human 
tonsils (Figure 3.15F).  CBX8 is thus an integral component of the PRC1-
BCOR complex in GC B cells in a RING1B- dependent manner.  
To evaluate the functional relevance of CBX8, we first examined whether it 
was recruited to bivalent promoters.  CBX8 binding was observed using qChIP 
assays in four DLBCL cell lines at the same six bivalent promoters evaluated 
earlier, but not at a negative control locus (Figure 3.15G).  To determine if 
CBX8 binding is linked to H3K27me3, we treated these cell lines with the 
EZH2 inhibitor GSK343 or GSK669 control.  In all cases, EZH2 inhibition 
resulted in profound loss of CBX8 recruitment (Figure 3.15G).  Next, to 
determine whether CBX8 was necessary for BCOR recruitment, we depleted 
CBX8 from GC-derived DLBCL cells using two independent shRNA or a 
control shRNA.  Both shRNAs induced significant reduction of CBX8 protein 
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(Figure 3.15H) and resulted in decreased BCOR recruitment to bivalent 
promoters, as well as reduction of the PRC1-BCOR complex catalyzed 
H2AK119ub histone mark (Figure 3.15I). 
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Figure 3.15 
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3.14 CBX8 phenocopies EZH2 loss-of-function in vitro and in vivo 
We observed that CBX8 was required for repression of key EZH2 bivalent 
genes including CDKN1A, PRDM1, and IRF4, since CBX8 shRNA resulted in 
their de-repression (Figure 3.16A).  To determine whether loss of CBX8 
mimics the effects of loss of EZH2, we examined the phenotype of DLBCL 
cells after CBX8 depletion relative to shRNA control in DLBCL cell lines.  In all 
cases, CBX8 loss results in significant growth suppression (t-test p < 0.001; 
Figure 3.16B).  We also observed induction of the plasma cell genes PRDM1, 
TP73, and CD138 by qPCR (Figure 3.16A).  Plasma cell differentiation was 
further demonstrated by decreased B cell surface marker CD20, increased 
plasma cell marker CD138, and surface expression of immunoglobulin heavy 
and light chains using flow cytometry (Figure 3.16C and D).  Morphologically, 
the DLBCL cells exhibited the characteristic features of plasma cell 
differentiation, including basophilic cytoplasm, eccentric more condensed 
nuclei, and prominent Golgi apparatus (Figure 3.16E). 
These data suggested that CBX8 is a required component of the PRC1-BCOR 
complex in GC B cells.  To confirm whether this is truly the case, we 
generated Cbx8fl/fl;Cγ1-cre mice301 and performed immunization experiments 
to induce GCs.  Cbx8 deletion resulted in marked depletion of GC B cells (t-
test p < 0.001; Figure 3.16F and G) and significant reduction in the number 
and volume of GCs (t-test p < 0.001; Figure 3.16H and I).  Together these 
results indicate that CBX8 is the component of the PRC1-BCOR complex that 
tethers the complex to chromatin downstream of the actions of EZH2, thus 
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enabling repression of bivalent promoters and mediating the actions of EZH2 
on GC formation. 
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Figure 3.16 
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3.15 Mutant EZH2 and constitutive BCL6 cooperate to induce 
lymphomagenesis 
Both EZH2Y641 mutation and BCL6 constitutive expression induce GC 
hyperplasia.  Having established the mechanistic basis for cooperation and 
interdependence of EZH2 and BCL6 in repressing critical GC B cell genes, we 
next examined whether their combined gain-of-function alleles might 
cooperate to drive the transformation of GC B cells to form DLBCLs.  BCL6 is 
constitutively expressed in the GCB-DLBCLs in which EZH2 somatic 
mutations occur.  Therefore, we crossed IµBcl6 with Ezh2(Y641F)fl/WT;Cγ1-cre 
mice to engineer BCL6 constitutive expression and mutant EZH2 activity in 
GC B cells.  The breeding resulted in four different allele combinations: IµBcl6 
alone, Ezh2(Y641F)fl/WT;Cγ1-cre alone, Ezh2(Y641F)fl/WT;Cγ1-cre;IµBcl6, and 
control littermates.  Bone marrow of these four groups was next transplanted 
into lethally irradiated recipient mice (Figure 3.17A).  Animals were immunized 
with SRBC every 3 weeks to ensure continuous formation of GCs and were 
observed for survival.  Ezh2(Y641F)fl/WT;Cγ1-cre;IµBcl6 mice showed 
significant acceleration of lethality compared with IµBcl6 and 
Ezh2(Y641F)fl/WT;Cγ1-cre mice (p = 0.001; Figure 3.17B).  A second cohort of 
mice (control n = 4, Ezh2(Y641F)fl/WT;Cγ1-cre n=4, IµBcl6 n=5, 
Ezh2(Y641F)fl/WT;Cγ1-cre;IµBcl6 n=12) was euthanized 223 days after 
transplant for more detailed phenotypic analysis.  Macroscopic examination of 
spleens and lymph nodes showed massive splenomegaly in 
Ezh2(Y641F)fl/WT;Cγ1-cre;IµBcl6 versus the other groups (t-test p < 0.05; 
	 120 
Figure 3.17C).  Histopathologic examination indicated that, whereas all 
Ezh2(Y641F)fl/WT; Cγ1-cre;IµBcl6 mice had developed a B cell lymphoma (FL 
or DLBCL n=10/12) or pre-neoplastic lymphoid hyperplasia (n=2/12), by 
contrast, none of the other groups showed either phenotype at this time point 
(Figure 3.17D).  These data suggest that mutant EZH2 and BCL6 cooperate 
to induce and accelerate the development of DLBCL-like disease.  
Figure 3.17 
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3.16 BCL6 and EZH2 Inhibitors Cooperate to Kill DLBCLs and Suppress 
Tumor Xenografts and Primary Human DLBCL Growth  
Both BCL6 and EZH2 inhibitors are proposed as potential therapies for 
patients with B cell lymphomas.  BCL6 and EZH2 are both constitutively 
expressed and required to maintain the growth of GCB-type DLBCLs, 
regardless of whether EZH2 is mutated.  Given that BCL6 and EZH2 
cooperate to induce maximal repression of their key target promoters, we 
asked whether simultaneously targeting both proteins might yield enhanced 
anti-lymphoma activity.  We exposed a panel of GCB-DLBCL cells to 
increasing concentrations of GSK343 in combination with FX1 (along with their 
respective controls).  In almost every case, the concentration of GSK343 
required to yield 50% growth inhibition was reduced when cells were 
concomitantly treated with FX1 (Figure 3.18A).  We also observed that EZH2- 
BCL6 bivalent target genes were significantly further de-repressed by 
treatment with the combination GSK343 and FX1 versus the single drugs (t-
test p < 0.01; Figure 3.18B).  Hence, targeting both arms of PRC1-BCOR 
tethering through EZH2 and BCL6 results in more powerful target gene de-
repression with corresponding greater biological activity against lymphoma 
cells.  
To determine the impact of combinatorial BCL6-EZH2 targeted therapy in a 
preclinical model, we evaluated the action of the EZH2 inhibitor GSK126 and 
FX1 alone or in combination at submaximal doses in mice bearing established 
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human DLBCL cell line (SUDHL6 and WSU-DLCL2) xenografts.  Although 
both EZH2 and BCL6 inhibitors suppressed tumor growth as single agents, the 
combination more potently and significantly suppressed lymphoma growth in 
vivo as demonstrated by growth curves and tumor weight (Figure 3.18C and 
D).  These data suggest that targeting BCL6 and EZH2 together may provide 
the basis for rational combinatorial therapies for GC-derived B cell 
lymphomas. 
	Figure 3.18 
3.17 Notes on analysis 
ChIPseq peak calling for broad and lowly enriched histone modifications is 
difficult and is often unreliably detected.  To overcome this, many studies have 
	 123 
examined ChIPseq read counts within gene promoter regions as a continuous 
quantification for occupancy.  Unfortunately, this approach does not allow for 
the identification of “occupied” versus “non-occupied” promoters and can 
hinder characterization of different chromatin features within the data, e.g. 
bivalent domains.  By identifying continuous regions with H3K27me3 ChIPseq 
enrichment greater than one standard deviation above the genome-wide 
mean, we were able to use the underlying structure of ChIPseq reads to 
determine loci where H3K27me3 exhibits clusters of 1kb bins with high 
enrichment.  As our approach smoothed the data to remove highly enriched 
bins with inconsistently enriched neighbors, we have selected for long, 
continuous regions and it is possible that our approach may have missed 
shorter and more acute enrichment over a few nucleosomes.  Despite such 
limitations, our H3K27me3 broad domain calling is supported both by 
association with gene repression (Figure 3.4D), EZH2 occupancy (Figure 
3.5C), and ChIP re-ChIP validation of enrichment (Figure 3.6D).  Furthermore, 
the identification of H3K27me3-occupied promoters allowed for key 
subsequent findings, including the establishment of GC B cell-specific de novo 
bivalent domains and cooperation of BCL6 and EZH2 to repress targets.	
 
3.18 Discussion 
Our work shows that EZH2 is a master regulator of the GC B cell phenotype, 
and that this function is aberrantly reinforced by mutant EZH2 lymphoma 
disease alleles (Illustration 3.1).  We find that EZH2 mediates its effects in 
GC B cells by repressing target genes involved in proliferation checkpoints 
(e.g., CDKN1A) and exit from the GC and terminal differentiation (e.g., IRF4 
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and PRDM1).  For immunoglobulin affinity maturation to occur, GC B cells 
must maintain their phenotype long enough to transit repeated rounds of 
division and somatic hypermutation.  Hence, in the absence of EZH2 function, 
which is needed to support the GC B cell phenotype, mice display defective 
immunoglobulin affinity maturation.  Normally, EZH2 levels decrease as B 
cells exit the GC reaction, enabling expression of genes that mediate terminal 
differentiation47.  However, in the presence of somatically mutated EZH2, 
suppression of GC exit genes and checkpoints persists, resulting in 
hyperplasia, and the presence of other oncogenic hits may enable 
transformation to GCB-type DLBCL.  An alternative route leading to GCB-
DLBCL could involve overexpression or aberrant maintenance of WT EZH2.  
Indeed, the highest quartile WT EZH2-expressing GCB-DLBCL display a trend 
toward increased repression of EZH2 targets and tend to cluster together with 
EZH2 mutant patients (data not shown).  The role of EZH2 in lymphomas is in 
large part to maintain or exaggerate (i.e., to hijack) the same EZH2 
transcriptional program required for development of normal GCs and 
immunoglobulin affinity maturation. Hence, GC B cells exhibit both oncogene 
and nononcogene addiction to EZH2.  
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Illustration 3.1 
 
The actions of EZH2 appear linked in part to de novo formation of bivalent 
chromatin domains, whereby genes marked by H3K4me3 in naive follicular B 
cells acquire H3K27me3 in GC B cells, concordant with upregulation of EZH2. 
In stem cells, bivalent domains are hypothesized to maintain genes in a 
repressed but poised conformation, which can be subsequently dynamically 
activated or repressed according to lineage-specific differentiation 
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programs225,302.  GC B cells represent a potentially unique situation where 
bivalent chromatin marks at specific genes are gained during differentiation, 
contrary to ES and tissue stem cell differentiation where bivalency is lost.  We 
cannot exclude, however, that other cell types and tumors that overexpress 
EZH2 might also form bivalent domains at promoters.  GC bivalent promoters 
are enriched in key gene sets involved in exit from the GC, such as IRF4- and 
CD40-induced genes, and genes upregulated in memory and plasma cells.  
As long as EZH2 maintains H3K27me3 at these loci, these genes are 
expressed at low levels, maintaining the GC phenotype.  As B cells exit the 
GC reaction and are selected for terminal differentiation, EZH2-mediated 
repression of these genes is terminated.  By contrast, EZH2 mutants disrupt 
the equilibrium of bivalent domains, enabling aberrant, persistent epigenetic 
silencing of genes and, in turn, allowing persistence of the GC B cell 
phenotype, facilitating lymphoid transformation.  Consistent with this 
hypothesis, we found that bivalent domain genes are aberrantly repressed 
with in EZH2 mutant DLBCL patient specimens.  These data, along with the 
recent identification of frequent loss-of-function mutations in the histone 
methyltransferase protein KMT2D in B cell lymphomas84,86, suggest that the 
balance of H3K4me3 and H3K27me3 is disrupted and represents a 
therapeutic target in lymphoid malignancies.  Mutations in KMT2D and EZH2 
in lymphoma are not mutually exclusive84, suggesting these mutations may 
cooperate to deregulate bivalent domains in GC B cells or that they also have 
independent roles in lymphomagenesis.  
 
EZH2 mutants may also mediate their actions through additional mechanisms. 
We and others have noted that H3K27 ChIPseq profiles as well as gene 
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expression profiles induced by EZH2 inhibitors are variable between cell 
lines93, suggesting that hyperactive EZH2 might lead to epigenetic instability 
and stochastic aberrant epigenetic silencing of different gene sets.  On the 
other hand, variability may be due to the genetic diversity of cell lines and, 
under the stress of continuous passage in vitro, the tendency to drift apart 
epigenetically.  This has been demonstrated in the case of cytosine 
methylation profiles, which differ considerably between lymphoma cell lines 
and primary lymphoma specimens189.  By contrast, primary human DLBCL 
specimens with mutant EZH2 showed a robust signature, consisting of greater 
repression of EZH2 target genes, including bivalent domains and with 
similarity to the EZH2 mutant signature induced in the isogenic BCL1 
experimental model.  Moreover, analysis of individual DLBCL cell lines after 
exposure to GSK343 showed upregulation of GC B cell EZH2 targets, 
including bivalent genes as well as phenotypic effects consistent with de-
repression of GC B cell EZH2 target genes.  Notably, these studies underline 
that EZH2-mediated epigenetic effects are reversible in lymphomas, which is 
consistent with data in the prostate cancer field also showing that suppression 
of EZH2 can result in reactivation of genes with tumor-suppressing 
activity303,304.  
 
Expression of mutant EZH2 alone in GC B cells was insufficient to induce 
development of DLBCL.  In this way, EZH2 mutation appears analogous to 
many of the somatic mutations in acute myeloid leukemia (AML), which induce 
a myeloproliferative phenotype when expressed in murine hematopoietic stem 
cells but, when expressed together, cooperate to form AML305.  Mutant EZH2 
induces a lymphoproliferative phenotype with expansion of the proliferative 
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GC B cell compartment.  Constitutive expression of the GC B cell oncoproteins 
BCL6 and BCL2 also manifest GC hyperplasia and a partially penetrant GC B 
cell lymphoma phenotype290,306.  Hence, even though normal GC B cells 
exhibit features of partially transformed cells, such as suppression of 
proliferative checkpoints and attenuated DNA damage response, multiple 
oncogenic hits are still required for overt lymphomagenesis.  This concept is 
supported by mutational profiling studies, revealing multiple concurrent 
somatic mutations in DLBCL specimens84,86, as well as our transplantation 
studies, demonstrating cooperation between mutant EZH2 and BCL2 in 
accelerating lymphomagenesis in mice.  Knowledge of the genetic 
composition of lymphomas and how these cooperate to transform B cells 
affords the opportunity to rationally design combinatorial therapies.  The 
enhanced anti-lymphoma activities of GSK343 and GSK503 in combination 
with anti-BCL2 therapies support this notion and point toward design of clinical 
trials geared toward the underlying biology of DLBCL and a reduced reliance 
on relatively nonspecific cytotoxic chemotherapy.  
 
While previous reports have focused on the role of EZH2 inhibitors against 
mutant-EZH2 DLBCL92-94, our data indicate that EZH2 is a relevant target 
beyond those tumors.  We find that GCB-type DLBCLs are dependent on wild-
type EZH2 for their proliferation and survival, regardless of somatic mutation, 
although response to EZH2 inhibitors is slightly delayed as compared to 
mutant EZH2 DLBCL cells.  This finding is in agreement with the absolute 
requirement of normal GC B cells for EZH2 and indicates that EZH2 is a 
lineage factor to which GCB-DLBCLs are addicted (Illustration 3.1).  By 
contrast, ABC-DLBCLs do not require EZH2 to maintain their proliferation and 
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survival.  Indeed, the target genes repressed by EZH2 consist of many of 
same genes that define the ABC-DLBCL sub- type.  These data provide a 
mechanism by which increased EZH2-mediated repression of target genes 
can impair B cell differentiation and demonstrate that therapeutic targeting of 
EZH2 in GCB-DLBCLs can induce differentiation and abrogate proliferation of 
GCB-DLBCLs with mutant or wild-type EZH2.  We thus provide the basis for 
the expanded clinical translation of EZH2 inhibitors for the treatment of GCB-
type DLBCLs.  Clinical studies with pharmacologic EZH2 inhibitors will 
determine if this approach can improve outcomes for lymphoma patients.  
Although many GCB-DLBCL cases can be cured with combination 
chemoimmunotherapy regimens, such treatments involve the use of toxic 
drugs that carry a lifelong risk of developing second malignancies.  The 
current standard therapy for B cell lymphomas (R-CHOP) wipes out the entire 
bone marrow of patients, and the B cell lineage is completely eradicated for 
months by rituximab (anti-CD20 antibody).  In comparison, the transient 
suppression of high-affinity antibody formation by EZH2 inhibitors seems less 
likely to be clinically significant.  By targeting the oncoproteins that drive and 
define the GCB-DLBCL phenotype, it may be possible to reduce our reliance 
on cytotoxic drugs to eradicate this disease.  
 
Additionally, we show that the GC phenotype and lymphomagenesis are 
mediated through cooperative and mutually interdependent actions of EZH2 
together with the transcriptional repressor BCL6.  Our data suggest a scenario 
whereby, within early GC B cells, BCL6, EZH2, CBX8, BCOR, and other 
noncanonical PRC1 components are upregulated while canonical PRC1 
components are repressed.  This allows the formation of a PRC1-BCOR 
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complex containing CBX8.  BCL6, a sequence-specific transcription factor, 
binds to gene promoters mostly through direct binding of its cognate DNA 
consensus site.  At the same time, EZH2 is recruited, via still largely unclear 
mechanisms, to a subset of the promoters of cell cycle- and differentiation-
associated genes bound by BCL6 and mediates H3K27 methylation of 
nucleosomes that were previously marked as active with H3K4me3 in mature 
resting B cells.  EZH2 and BCL6 appear to arrive at these genes 
independently and do not physically interact.  What ensues is a form of 
combinatorial tethering, whereby the presence of BCL6 and H3K27me3 at 
bivalent chromatin formed by EZH2 is required for the stable recruitment of the 
BCOR-CBX8 noncanonical PRC1 complex (Illustration 3.2).  However, 
neither BCL6 binding to BCOR nor CBX8 binding to H3K27me3 alone is 
sufficient to maintain the association of the BCOR complex.  Notably, binding 
of BCOR to BCL6 occurs with surprisingly low affinity (~20 mM) given the 
extended binding surface between these two proteins.  Among CBX proteins, 
CBX8 has relatively lower binding affinity for H3K27me3307 and may only 
result in metastable binding. Apparently, both of these independent protein 
interactions are required to sustain and stabilize the association of BCOR with 
this particular set of key GC B cell promoters.  Thus engaged, the PRC1-
BCOR-CBX8 complex then mediates PRC1 functions, including H2AK119 
ubiquitylation and, in turn, putatively contributing to repression of transcription 
at these loci.  Notably, CBX8 has not been previously implicated in B cell 
biology or lymphomagenesis.  The fact that CBX8 loss-of-function 
recapitulates the effects of EZH2 loss in normal and malignant GC B cells 
speaks to its critical function in this cellular context.  
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Illustration 3.2 
 
Our proposed model of combinatorial tethering conceptually links the 
proposed “instructive” versus “sampling“ modes of action for PRC2 
functionality308.  In this instance, neither instructive (transcription factor-
directed) nor sampling (PRC2-directed) modes are sufficient to direct PRC1 
recruitment and instead the complexes must cooperate for cell context-specific 
gene repression.  Thus, PRC2-mediated formation of bivalent chromatin at 
specific promoters in B cells provides a required link to support a 
stoichiometrically weak interaction between transcription factors and their co-
repressors.  By the same token, BCL6 binding to BCOR is insufficient to 
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Illustration 3.2.  Combinatorial tethering mediates noncanonical PRC1-BCOR complex.  EZH2 
and BCL6 cooperate to recruit a noncanonical PRC1-BCOR complex containing CBX8 to repress
expression of differentiation-associated genes in GCBs and promote lymphomagenesis.  Targeting
both BCL6 and EZH2 for inhibition elicits strong anti-lymphoma activity in DLBCL.
	 132 
sustain and stabilize its activity and requires the independent action of EZH2.  
Combinatorial tethering may also help to explain certain puzzling aspects of 
transcriptional repression.  For example, BCL6 is known to bind to many 
promoters, yet only represses the subset of these where it forms a complex 
with BCOR41.  Perhaps the combined actions of BCL6 and H3K27me3 
together represent a combinatorial code that limits the formation of competent 
repression complexes only to sites relevant to GC B cells.  Indeed, the genes 
where this combinatorial mechanism occurs are critical for the GC phenotype, 
such as CDKN1A, CDKN1B, IRF4, and PRDM1.  In contrast, BCL6 and BCOR 
are mostly excluded from monovalent H3K27me3 domains, and hence are not 
involved in repressing these regions.  
 
It remains possible that PRC1, PRC2, and BCL6 function to mutually sustain 
and stabilize their respective binding in bivalent promoters. Along these lines, 
Kalb et al. identified a positive feedback loop in which H2Aub promotes PRC2 
binding and H3K27 trimethylation, and H3K27me3, in turn, promotes binding 
of canonical PRC1309.  H2A ubiquitylation mediated by noncanonical 
complexes was shown to facilitate recruitment of PRC2 in embryonic stem 
cells engineered to contain a Polycomb tethering sequence310.  Recruitment of 
PRC2 was also reported to occur through canonical PRC1-mediated H2A 
ubiquitylation311.  Indeed, our data hint at additional aspects of Polycomb 
functionality.  For example, the finding that disruption of the BCL6-BCOR 
interaction reduces EZH2-mediated H3K27me3 without loss of PRC2 complex 
binding could be linked to EZH2 requirement for H2A ubiquitylation; or to 
impaired PRC2 function due to increasing H3K36 methylation because of loss 
of KDM2B312.  Indeed, H3K36me2 was increased after treating three different 
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GCB-DLBCL cell lines with GSK343 or after disrupting BCL6-BCOR 
interaction with FX1 (data not shown).  Collectively, the combinatorial tethering 
model expands notions on how transcription factors and Polycomb complexes 
can work integratively to direct gene-specific repression.  It is important to also 
underline that these results do not explain all the effects of BCL6, EZH2, and 
BCOR in B cells.  For example, BCOR binds to many promoters independent 
of the presence of BCL6 and it was recently shown in embryonic stem cells 
that KDM2B, a subunit of the PRC1-BCOR complex, can contribute to 
recruitment of noncanonical PRC1 complexes via binding of its CXXC motif to 
unmethylated CpG islands313,314.  Our analysis of BCOR distribution in GC B 
cells suggests that a similar mechanism may be at play at different sets of 
target genes independent of the BCL6-EZH2 mechanism described herein41.  
 
Constitutive expression of BCL6, as well as somatic mutation of EZH2, can 
prevent the resolution and sustain the GC phenotype, potentially explaining 
how they induce lymphomas.  We have shown that this is partially linked to 
their common action in the combinatorial tethering of the noncanonical PRC1-
BCOR complex to bivalent chromatin domains formed during the humoral 
immune response.  The enhanced anti-lymphoma activity observed by 
combining EZH2 with BCL6 inhibitors is likely, at least in part, due to more 
profound disruption of bivalent gene repression, as the combination results 
further increased expression of these transcripts.  Administration of BCL6 and 
EZH2 inhibitors may thus constitute a mechanism-oriented rational 
combinatorial therapy by disabling both arms of the PRC1-BCOR tethering 
mechanism.  
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3.19 Material and methods 
Murine models  
Conditional Ezh2 knockout mice (loxP-flanked Ezh2 allele, Ezh2fl/fl) were a 
generous gift of Dr. Alexander Tarakhovsky, The Rockefeller University50.  By 
crossing Ezh2fl/fl with the transgenic Cγ1cre strain (The Jackson Laboratory, 
010611), we generated heterozygous Ezh2fl/WT mice, which were crossed to 
yield Ezh2fl/fl mice.  As control group, we used Ezh2fl/fl Cγ1cre negative 
littermates.  Ezh2(Y641F)fl/WT, Bcl6fl/fl, and Bcorfl mice were crossed with 
Cγ1cre strain.  The Cγ1cre negative littermates were used as control groups.  
IµBcl6 were obtained from Dr. Ricardo Dalla-Favera, Columbia University290.  
The conditional Bcor allele (Bcorfl which is on the X chromosome), which 
contains loxP sites flanking Bcor exons 9 and 10, was generated by 
homologous recombination (M.Y. Hamline, C.M. Corcoran, J.A. Wamstad, 
M.D. Gearhart, I. Miletich, J. Feng, M. Hemberger, P.T. Sharpe, and V.J. 
Bardwell, manuscript in preparation).  CRE-mediated deletion results in a 
premature stop codon and a Bcor null allele.  Conditional Bcl6 knockout mice 
(loxP-flanked Bcl6 allele, Bcl6fl/fl) were generated by Taconic315.  Cbx8fl were 
obtained from Dr. Haruhiko Koseki, Riken Center, Japan301.  Bcl6BTBmut mice 
were developed as previously described43.   All knockout, knock-in and 
transgenic mice were used for assessment of the germinal center formation, 
which were induced with SRBC.  
Germinal center assessment in mice  
The Research Animal Resource Center of the Weill Cornell Medical College of 
Medicine approved all mouse procedures. Age- and sex-matched C57BL6 
mice were immunized intraperitoneally at 8 to 12 weeks of age with 0.5 ml of a 
2% sheep red blood cell (SRBC) suspension in PBS (Cocalico Biologicals), or 
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100 µg of highly substituted NP-KLH (NP-25 Keyhole Limpet Hemocyanin, 
Bioresearch Technologies) in alum (Thermo Scientific), and sacrificed after 10 
or 14 days, respectively.  
For GSK503 and FX1 experiments: drug or vehicle (20% captisol for GSK503, 
and 30% PEG-300 + 3% dextrose + 5% Tween-80 for FX1) was injected 
intraperitoneally starting the following day after induction of GC by SRBC and 
administered daily at a concentration of 150 mg/kg/day GSK and 50 
mg/kg/day FX1 for 9 consecutive days after which the mice were sacrificed 
(day 10).  
Flow cytometry analysis  
Analysis of splenocytes: single-cell suspensions from mouse spleens were 
stained using the following fluorescent-labeled anti-mouse antibodies: PE-Cy7 
conjugated anti-B220, PE-Cy7 conjugated anti-CD21, PE conjugated anti-
CD23, APC conjugated anti-IgM (eBioscience), APC conjugated anti-B220, PE 
conjugated anti-FAS, APC conjugated anti-CD38, FITC conjugated anti-GL7, 
PE conjugated anti-IgD (BD Bioscience), AlexaFluor488 conjugated anti-
EZH2, AlexaFluor488 conjugated IgG1κ isotype control (BD Biosciences). 
DAPI was used for the exclusion of dead cells.  
Analysis of cell lines: cells were stained using the following fluorescent-labeled 
anti-human antibodies: PE conjugated anti-CD20, PE-Cy5.5 conjugated anti-
CD20, FITC conjugated anti-CD138, PE-Cy5.5 conjugated anti-IgM, PE-Cy7 
conjugated anti-CD27, APC conjugated anti-IgG1, APC conjugated anti-
annexinV (all from BD Bioscience), multimix for plasma cells (FITC conjugated 
anti-CD19, PE conjugated anti-Ig lambda, APC conjugated anti-Ig kappa) and 
isotype control multimix (Dako). To evaluate total levels (cytosolic+cell 
surface) of Igλ, Igκ, IgM and IgG1, cells were permeabilized with BD 
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Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences). 
Data were acquired on MacsQuant flow cytometer (Miltenyi Biotec) and 
analyzed using FlowJo software package (TreeStar).  
Immunohistology and diagnosis  
Mice organs were fixed in 4% formaldehyde and embedded in paraffin. 
Deparaffinized slides were antigen retrieved in citrate buffer pH 6.4 and 
endogenous peroxidase (HRP) activity was blocked by treating the sections 
with 3% hydrogen peroxide in methanol.  Indirect immunohistochemistry was 
performed with antispecies-specific biotinylated secondary antibodies followed 
by avidin–horseradish peroxidase or avidin-AP, and developed by Vector Blue 
or DAB color substrates (Vector Laboratories).  Sections were counterstained 
with hematoxylin if necessary.  The following antibodies were used: biotin-
conjugated anti-PNA (Vector Laboratories), biotin-conjugated anti-B220 
(Invitrogen RM2615), EZH2 (Cell Signaling 5246), Ki67 (Vector VP- K451), 
CD3 (Vector VP-RM01).  Slides were scanned using a Zeiss Mirax Slide 
Scanner and photomicrographs were examined with Panoramic Viewer 
software.  ImageJ 1.44o software (NIH) was used to quantify germinal center 
areas.  
H&E and IHC stained sections were examined by a board certified veterinary 
pathologists and lesions were classified based on morphologic features and 
marker expression, according to the classification system for murine lymphoid 
neoplasms of the hematopathology subcommittee of the Mouse Models for 
Human Cancers Consortium, United States National Cancer Institute316.  
ELISA  
Murine serum samples were collected 14 days after NP-KLH immunization 
and immunoglobulin levels were analyzed by ELISA.  Sera were tested for the 
	 137 
binding of NP-specific IgG1, IgG2a, IgG2b and IgG3 antibodies 
(SouthernBiotech) to NP4-BSA coated plates.  
Immunoblotting  
Lysates from splenocytes and DLBCL cells were prepared using 20 mM Tris, 
pH 8, 135 mM NaCl, 1% NP-40, 10% glycerol, 1 mM PMSF, and complete 
protease inhibitor cocktail (Roche) lysis buffer.  Lysates for nuclear fractions of 
BCL1 cells were obtained using the Nuclear Complex Co-IP Kit (Active Motif).   
Protein lysates were resolved by SDS-PAGE, transferred to PVDF membrane, 
and probed with the indicated primary antibodies: EZH2 (Active Motif 39933 
and BD 612666), H3K27me3 (Millipore 07-449 and 17-622), EED (Millipore 
09-774), SUZ12 (Santa Cruz sc-67105), FLAG (Sigma F1804), p21 (Cell 
Signaling 2947), pan-Histone 4 (Abcam ab7311), pan-Histone 3 (Millipore 07-
690), αTubulin (Sigma), rabbit polyclonal antibodies were raised against 
BCOR, KDM2B, and PCGF1 using glutathione S-transferase (GST) fusions of 
human BCOR(C) (1035-1230), human KDM2B (726-817), and human PCGF1 
(128-189) and subsequently affinity purified (Gearhart et al., 2006); RING1B 
(Bethyl A302-869A), CBX8 (Bethyl A300-882A), BCL6 (Santa Cruz sc-7388), 
BCL6 (Santa Cruz sc-858), H2AK119ub1 (Cell Signaling 8240), αTubulin 
(Sigma), βActin (Sigma A5441), myc (Santa Cruz 9E10).  Membranes were 
then incubated with a peroxidase-conjugated correspondent secondary 
antibody and detected using enhanced chemiluminescence.  Densitometry 
values were obtained by using ImageJ 1.44o software (NIH).  
Immunoprecipitation  
Lysates from DLBCL cells were prepared using 25 mM Tris, pH 8, 150 to 250 
mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 1 mM 
PMSF, and complete protease inhibitor cocktail (Roche) lysis buffer.  Two µg 
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of antibodies were added to the precleared sample and incubated overnight at 
4°C.  The complexes were purified using protein-A beads (Roche) followed by 
elution from the beads using SDS load buffer.  
Full length human CBX8, PCGF1, RNF2, the short isoform of KDM2B (derived 
from the second promoter after the sequences encoding the JmjC domain) 
and the carboxy-terminus of BCOR (amino acids 1562-1755) were cloned into 
myc- or myc-flag-tagged versions of the pIEx-4 expression vector (EMD 
Millipore #71235).  Mutations were made in CBX8 and RNF2 using PCR 
subcloning and confirmed by sequencing.  Sf9 insect cells were transiently co-
transfected as indicated using Insect GeneJuice Transfection Reagent (EMD 
Millipore #71259).  Cells were harvested after 68 hours in 0.5 ml lysis buffer 
containing 1X phosphate buffered saline, 10% glycerol, 0.1% NP-40, 1 mM 
dithiothreitol (DTT), 2 mM sodium fluoride, 0.2 mM PMSF, and complete 
protease inhibitor cocktail without EDTA (Roche #11873580001).  The extracts 
were sonicated for 10 seconds at 25% power with a stepped micro tip, 
centrifuged at 12,000 g and supplemented with 2 mM MgCl2and 25 U / 
sample Benzonase (EMD Millipore #70746).  Lysates were incubated with 
Anti-Flag M2 Agarose Affinity Gel (Sigma #A2220) for 2 hours at 4°C with 
gentle agitation.  The affinity gel beads were washed in lysis buffer and boiled 
in 1x LDS sample buffer (Thermo Fisher #NP0007) supplemented with 5% 
beta-mercaptoethanol.  Proteins were resolved on a 4-12% Bis-Tris NuPage 
Gel in MOPS buffer (ThermoFisher #NP0322 and #NP0001) and transferred 
to 0.45µM nitrocellulose membrane (NitroBind #1215471).  Blots were 
incubated with anti-Myc (1:500 dilution 9E10 Santa Crux #SC-40) and 
visualized with either Alexa Fluor 680-conjugated Goat Anti-Mouse IgG 
(H+L)(input samples, 1:500 dilution Jackson ImmunoResearch #115-625-166) 
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or TrueBlot Anti-Mouse Ig DyLight 680 (immunoprecipitates, 1:250 dilution 
Rockland #18-4417-32) using an Odyssey Scanner (Li-Cor Biosciences).  
For HEK293 immunoprecipitations the WT and mutant form of CBX8 were 
subcloned into an EF1a driven His- CBP-3XFlag lentiviral vector that co-
expresses eGFP.  Virus particles were produced using an empty vector control 
and the two CBX8 constructs in HEK293 cells and subsequently used to 
transduce freshly seeded HEK293 cells with nearly 100% efficiency based on 
eGFP.  Cells were expanded for 5 days and immunoprecipitations were 
carried out as above Sf9 insect cell experiments.  
Cell lines  
The DLBCL cell lines OCI-Ly1 (EZH2Y641N) and OCI-Ly7 (WT EZH2) were 
grown in Iscove’s medium supplemented with 10% FBS and penicillin 
G/streptomycin; the DLBCL cell lines Farage (WT EZH2), WSU- DLCL2 
(EZH2Y641F), Pfeiffer (EZH2A677G), SUDHL6 (EZH2Y641N), SUDHL5 (WT EZH2) 
and SUDHL4 (EZH2Y641S) were grown in RPMI medium supplemented with 
10% FBS, penicillin G/streptomycin, l-glutamine, and HEPES. Sf9 insect cells 
(Novagen #71104-3) were maintained in suspension in logarithmic phase in 
serum-free medium at 28°C and 150 rpm agitation.  
ChIP, ChIP re-ChIP and qPCR  
ChIP was performed as previously described45.  Briefly, 1e+08 cells were fixed 
with 1% formaldehyde, lysed, and sonicated (Branson Sonicator; Branson) 
leading to a DNA average size of 200 bp. Five µg of antibodies anti-EZH2 
(Active Motif 39901), RING1B (Bethyl A302-869A), CBX8 (Bethyl A300-882A), 
BCL6 (Santa Cruz sc-858), H3K27me3 (Abcam 6002), H2AK119ub1 (Cell 
Signaling 8240), H3K36me2 (Active Motif 39255), EED (Millipore 09-774), 
SUZ12 (Santa Cruz sc-67105), BCOR, KDM2B, PCGF1293 or control IgG 
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(Millipore) were added to the precleared sample and incubated overnight at 
4°C.  The complexes were purified using protein-A beads (Roche) followed by 
elution from the beads and decrosslinking.  DNA was purified using PCR 
purification columns (QIAGEN). For ChIP re-ChIP experiments, chromatin 
immunoprecipitates were eluted with DTT and then subjected to a second 
round of immunoprecipitation with the indicated antibodies or IgG.  ChIP and 
ChIP re-ChIP DNA was amplified by real-time quantitative PCR using 
SyberGreen (Applied Biosystems) on 7900HT Fast Real-Time PCR System 
(Applied Biosystems).  
Plasmids and shRNAs  
EZH2 cDNA was cloned into pRetroX-ZsGreen vector (Clontech) and Y641X 
mutations were made using QuickChange Lighting Site-Directed Mutagenesis 
Kit (Stratagene) following manufacturer’s recommendation.  Retroviruses were 
produced by transfection of amphotropic 293T cells with appropriate plasmids 
and FuGENE 6 Transfection reagent (Roche).  shRNAs were delivered by 
lentivirus infection, which were produced by transfection of 293T cells with the 
vector pLKO.1.  For shRNA anti-EZH2 we used the pLKO.1-YFP vector, and 
infected cells were identified by YFP expression by flow cytometry.  For CBX8 
we used pLKO.1-puro, and infected cells were selected by puromycin 
treatment (1µg/mL).  Mature antisense sequences of shRNA used to 
knockdown EZH2 and CBX8 were: shEZH2#2: 5’-
TTTGGTCCCAATTAACCTAGC-3’, shEZH2#3: 5’- 
TAATGGGATGACTTGTGTTGG-3’, shCBX8#2: 5’-
AAAGTTTGAGGTCACGTCCGT-3’, shCBX8#4: 5’- 
TTACTTTCCTTAATGGTGACG-3’.  
Proliferation and differentiation assays  
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Cells were plated in triplicate (100,000 BCL1 cells/mL and 500,000-800,000 
DLBCL cells/mL) and live cells were counted at indicated days using either 
trypan blue exclusion or flow cytometry using annexinV and DAPI exclusion.  
The experiments were performed with two different biological replicates and 
data is presented as average of six counts +/- standard deviation.  Every four 
days, cells were replated at initial concentration with fresh media and inhibitors 
if necessary.  To induce differentiation, BCL1 cells were treated with 20ng/mL 
of recombinant mouse IL-2 and IL-5 (R&D Systems).  Cells were counted at 
day 3 and were replated in the presence of cytokines for additional two days.  
Growth inhibition and combination of drugs  
DLBCL cell lines were grown at concentrations sufficient to keep untreated 
cells in exponential growth over the complete drug exposure time.  Cell 
viability was determined using a fluorometric resazurin reduction method 
(CellTiter-Blue, Promega) and trypan blue automatic method (TC10, BioRad). 
Fluorescence (Ex560nm / Em590nm) was determined with the Synergy4 
microplate reader (BioTek).  The number of viable cells was calculated by 
using the linear least-squares regression of the standard curve.  The 
fluorescence was determined for three replicates per treatment condition and 
normalized to their respective controls.  To plot dose-effect curves CompuSyn 
software (Biosoft) was used, and drug concentrations that inhibits the growth 
of the cell lines by 50% compared to control (GI50) were determined.  Data 
were presented as the mean GI50 with a 95% confidence interval for duplicate 
experiments.  In the experiments using combination of drugs, DLBCL cell lines 
were exposed to 5 concentrations of GSK343 or GSK503 for 6 days followed 
by 5 concentrations ABT-737 (Selleck) or Obatoclax (Selleck) for additional 
48h and analyzed for cell viability as before.  To quantify the effect of the 
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sensitization, we calculated the dose reduction index (DRI) at GI90 using 
CompuSyn software.  The DRI is a measure of how many fold the dose of 
each drug in a combination may be reduce at a given effect level compared 
with the doses of each drug alone and is based on the equation DRI = (Dx)1 / 
(D)1, were (Dx)1 represent the dose of drug 1 for a given effect x and were 
(D)1 represent the dose of drug 1 given in combination to reach the same 
effect x.  
Microarray analysis with DLBCL patient samples  
DLBCL patient samples were hybridized to Affymetrix HG-U133 Plus 2.0 
microarrays. Affymetrix data were extracted, normalized and summarized with 
the RMA method from Bioconductor's 'affy' package, using the default 
settings, and remapped to the newest annotated RefSeq genes317.  
BCOR and PCGF1 tandem affinity purifications  
For mammalian expression, stable cell lines of HEK293 cells were generated 
by infection with ProtA2-TEV- CBP-Flag-Pcgf1293, His-CBP-3XFlag-Bcor(A)-
HA, and His-CBP-3XFlag-HA retroviruses.  Bcor isoform a cDNA was tagged 
at the N-terminus with tandem His tag, calmodulin binding peptide, and three 
copies of the Flag tag, and at the C-terminus with HA.  This or just the affinity 
tags were then cloned into a modified version of pLentiLox3.7 (containing a 
shortened version of the EF promoter and beta globin 5` untranslated region 
and a GFP blasticidin fusion gene) creating His-CBP-3XFlag-Bcor(A)-HA, and 
His-CBP- 3XFlag-HA encoding retroviruses. All nucleotides of inserts were 
verified by sequencing. Cells were cultured in Dulbecco’s minimal essential 
medium (Cellgro) with 5% calf serum (Biosource) and 5 µg/ml blasticidin (or 1 
µg/ml puromycin for the Pcgf1 cells). Nuclear extracts were supplemented with 
0.1% NP-40, 0.1% Tween, 2 mM EGTA, and 0.5 mM EDTA and incubated 
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with M2-agarose (Sigma) overnight. Beads were washed in 50 mM Tris pH 8, 
1 mM MgCl2, 1 mM imidazole, 0.1% NP-40, 20% glycerol, 2 mM DTT, 2 mM 
PMSF, 2 mM EGTA, 0.5 mM EDTA, protease inhibitor cocktail (Complete 
EDTA-free; Roche), and 350 mM KCl (TGN350). Complexes were eluted with 
30% yields using 2 mg/ml Flag peptide, substituting 2 mM CaCl2 for EGTA 
and EDTA in the TGN350 buffer, and recaptured with calmodulin-sepharose 
(GE HealthCare). Calmodulin beads were washed with TGN350 and stripped 
of protein using 100 mM Tris pH 8.5 with 8 M urea, heated at 37oC for 1 hour. 
For visualization, protein samples were resolved on a 4-12% NuPAGE Novex 
Bis-Tris gel in MOPS running buffer (Invitrogen) and visualized by silver 
staining (SilverQuest; Invitrogen). For mass spectrometry analysis, complexes 
were submitted for trypsinization and analysis at the University of Minnesota 
Center for Mass Spectrometry and Proteomics.  
Mass Spectrometry data analysis  
Mass spectrometry analysis of H3K27 methylation was performed as 
described previously318.  The amount of H3K27me3 mark was calculated as a 
percentage of a peptide encompassing amino acids 27-40 from histone H3.  
Samples were analyzed using liquid chromatography mass spectrometry (LC-
MS) on an Orbitrap LTQ mass spectrometer.  Proteins were identified by 
searching human protein databases with Sequest.  Peptide identification and 
protein coverage were calculated using Sequest and Scaffold.  Proteins 
identified in the corresponding empty vector control purification were 
eliminated from each purification list.  In addition, proteins previously found to 
bind affinity tags non-specifically were eliminated from each purification list319.  
Proliferation assays  
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Cells were plated in triplicate (500,000-800,000 DLBCL cells/ml) and live cells 
were counted at indicated days using a fluorometric resazurin reduction 
method (CellTiter-Blue, Promega).  The experiments were performed with two 
different biological replicates and data is presented as average of six counts 
+/- standard deviation.  Every three days, cells were replated at initial 
concentration with fresh media.  
B cell purification and characterization  
Human B cell populations were affinity-purified from de-identified human 
tonsillectomy specimens using standard protocols45 with approval from the 
Human Research Protections Programs, Division of Research Integrity of the 
Weill Cornell Medical College, in accordance with the Declaration of Helsinki.  
NB and GC B cell purity was determined by flow cytometry analysis of surface 
IgD (BD Pharmingen), CD77 (AbD Serotech) and CD38 (BD Pharmingen).  
DLBCL patient samples  
Patient-deidentified leftover tissues were obtained at diagnosis from patients 
with de novo DLBCL in Vancouver at the British Columbia Cancer Agency.  
Cases were selected on the basis of the presence of at least 80% of the 
neoplastic cells within the tumor section.  Patient samples were co-cultured 
with irradiated HK stromal cells and were kept in culture for no longer than 5 
days, given that primary DLBCL cells do not proliferate or maintain their 
viability for very long in culture.  
RT-qPCR  
RNA was prepared using Trizol extraction (Invitrogen).  cDNA was prepared 
using cDNA synthesis kit (Thermo Scientific) and detected by fast SyberGreen 
(Applied Biosystems) on 7900HT Fast Real-Time PCR System (Applied 
Biosystems).  We normalized gene expression to HPRT1 or GAPDH and 
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expressed values relative to control using the ΔΔCT method.  Results were 
represented as fold expression with the standard deviation for 2 series of 
triplicates.  
Primers used for qPCR  
Used for  Gene  
 
Oligonucleotide (5'-3')  
cDNA IRF4  Fwd  AGAAGAGCATCTTCCGCATC  
  
Rev  CCTTTAAACAGTGCCCAAGC  
 
PRDM1  Fwd  CTACCCTTATCCCGGAGAGC  
  
Rev  GCTCGGTTGCTTTAGACTGC  
 
CD138  Fwd  GAGCAGGACTTCACCTTTGA  
  
Rev  TTCGTCCTTCTTCTTCATGC  
 
CDKN1A  Fwd  GGAAGACCATGTGGACCTGT  
  
Rev  TAGGGCTTCCTCTTGGAGAA  
 
TP73  Fwd  CTCCACCTTCGACACCATGT  
  
Rev  GGACACCTTGATCTGGATGG  
 
BMI1  Fwd AATCCCCACCTGATGTGTGT  
  
Rev GGTCTGGTCTTGTGAACTTGG  
 
BCOR  Fwd CGATGCCTATAGCGATGTGTT  
  
Rev  TCCGAAAGCAGTAGCCAGTT  
 
PCFG1 Fwd  GAGACACAGCCACTGCTCAA  
  
Rev ATTCCCGAATCCGTTTCTCT  
 
PCGF2 Fwd CATCGGACTACACGGATCAA  
  
Rev CACACATGGGGCAGTATTTG  
 
CBX8 Fwd GCATGGAATACCTCGTGAAA  
  
Rev CTCAAAGGCTGCGAGCAAG  
 
GAPDH Fwd CGACCACTTTGTCAAGCTCA  
  
Rev CCCTGTTGCTGTAGCCAAAT  
 
HPRT1 Fwd AAAGGACCCCACGAAGTGTT  
  
Rev TCAAGGGCATATCCTACAACAA  
 
Bcor  ex2-3 Fwd ATGCTTTCTGCAACCCCTCT  
  
Rev AGGGGAGTCTCCTCCCTCAG  
 
Bcor ex8-9 Fwd AGAGAAGCCTGGCAGGAAA  
  
Rev GCTTGGCTGAGTCTGCTTTT  
 
Bcor ex14-15 Fwd  TTGCTGAAAGCTCCCTCTTG  
  
Rev TAAAACTCCGCCTCTGCAAT  
 
Ezh2 Fwd   ATCTGAGAAGGGACCGGTTT 
  
Rev  GCTGCTTCCACTCTTGGTTT  
 
Gapdh Fwd  CTGCACCACCAACTGCTTAG  
  
Rev  GGATGCAGGGATGATGTTCT  
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ChIP IRF4 Fwd  CGACTCCCACCCCATCTG  
  
Rev  CGACAGTCCGGTTAGCTCAT  
 
PRDM1_1 Fwd  GTCCGGTGAGCACAAAATTC 
  
Rev  TCTTCCCCTCTTTTTAGGAGGT 
 
PRDM1_2 Fwd  CAGAATTCACCCAGCCTTGT  
  
Rev  CAGGCGGTAAACACCAGAAT  
 
CDKN1A Fwd  CAGTGGACCTCAATTTCCTCA  
  
Rev  AAAACGATGCACCTCTCTGC  
 
CDKN1B_1 Fwd  CGAAGAGTTAACCCGGGACT 
  
Rev  AGTAGAACTCGGGCAAGCTG 
 
CDKN1B_2 Fwd  CAGGTTTGTTGGCAGCAGTA  
  
Rev  AGGAGGAGATCCATTGGTTG  
 
HOXA7 Fwd  GCTAAAAAGCGCGTTCACAT 
  
Rev  GCTCCGTCCAAAAGAAAATG 
 
BCL6 Fwd  GCAGTGGTAAAGTCCGAAGC 
  
Rev  AGCAACAGCAATAATCACCTG 
 
ARID3A Fwd  TGGAGACTTCACTCCCCACT  
  
Rev  CTACCCTCCCTCCTCTCTGG  
 
ARID3B Fwd  CCAACCTCCGCAATAGAAAA  
  
Rev  ACTGAGTTGTGGGAGGAAGC  
 
Negative control 
region_1 Fwd  TAGCTGGGAAGCTGGGACTA 
  
Rev  GGTTTCCTTGCCCTAAAAGG 
 
Negative control 
region_2 Fwd  AACCTGCAAAACATGGTTATTT  
  
Rev AATTTGCCCAAACAGCAAGT  
 
ChIPseq and mRNAseq library preparation and Illumina sequencing 
processing  
ChIPseq and RNAseq libraries were prepared using the Illumina ChIPseq and 
TruSeq RNA sample kits, respectively, according to the manufacturer.  
Libraries were validated using the Agilent Technologies 2100 Bioanalyzer and 
Quant-iTTM dsDNA HS Assay (Life Technologies), and 8-10 pM sequenced 
on HiSeq2000 sequencer as follows: ChIPseq, 1 x 50; mRNAseq, 2 x 50.  
RNA sequencing results were aligned to mm10 using STAR278 and annotated 
to RefSeq using the R subread package279.  
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were identified using the EdgeR package GLM320 with thresholds of fold-
change >1.5 and p<0.01, adjusted for multiple testing using Benjamini-
Hochberg correction.  ChIPseq experiments from human B cells, human cell 
lines and murine cells were aligned to the hg18, hg19 and mm9 genome, 
respectively using ELAND.  H3K4me3, BCL6 and BCOR ChIPseq reads were 
called into peaks using the ChIPseeqer framework (p<10-15 and fold-change 
threshold 2)277 and H3K27me3 and EZH2 ChIPseq reads were quantified in 
1kb bins genome-wide, identifying regions of enrichment as consecutive bins 
with read counts greater than one standard deviation of the genome-wide 
mean.  
ChIPseq and mRNAseq analysis GCB-specific H3K27me3 targets: 
H3K27me3 ChIPseq read counts were determined for all regions +/- 2kb of 
RefSeq TSS for naive B cells and GC-B cells, normalizing for total ChIPseq 
reads.  Promoter regions with 1.5- fold greater H3K27me3 ChIPseq reads in 
GCB cells and corresponding RNAseq gene expression 1.5-fold greater in 
GCB cells relative to naive B cells were identified. GSK343-responsive 
genes: RNAseq was performed in OCI-Ly7, OCI-Ly1, SUDHL5, Farage, 
WSU-DLCL2 and Pfeiffer cells treated with 2 µM GSK343 or GSK669 for 7 
days.  Gene expression ratios were determined in cells treated with GSK343 
compared to cells treated with GSK669 and were identified using Cufflinks. 
GSK343- responsive genes were identified as genes that were upregulated 
1.2-fold in four cell lines. shEZH2-responsive genes: RNAseq was performed 
in OCI-Ly7, OCI-Ly1, SUDHL5, Farage and WSU- DLCL2 cells transduced 
with shRNA for EZH2 or control shRNA for 7 days. Gene expression ratios 
were determined in cells transduced with EZH2 shRNA compared to cells 
transduced with control shRNA and were identified using Cufflinks.  shEZH2-
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responsive genes were identified as genes that were upregulated 1.2-fold in 
four cell lines. Plasma/Memory Cell Signature: RNAseq was performed in 
three replicates of plasma cells, three replicates of memory cells, and four 
replicates of GCB cells.  The plasma/memory cell signature was determined 
as the union of genes upregulated 1.5-fold in plasma cells or memory cells 
compared to GCB cells. Genes with increased H3K27me3 in mutant EZH2 
BCL1 cells: H3K27me3 ChIPseq read counts were determined for all regions 
+/- 2kb of RefSeq TSS for BCL1 cells transduced with WT EZH2, Y641F 
EZH2, or Y641N EZH2, normalizing for total ChIPseq reads.  Promoter 
regions with 1.5-fold greater H3K27me3 ChIPseq reads in mutant BCL1 cells 
were identified.  Gene expression ratios were determined in BCL1 transduced 
cells treated with 0.5 µM GSK343 compared to cells treated with 0.5 µM 
GSK669 for 3 days and were identified using Cufflinks.  A 0.5 µM dose was 
used since it was sufficient to at least partially reverse H3K27me3, whereas 
2.5 µM were used in functional assays since this corresponds to the IC50 for 
this drug.  
Gene Set Enrichment Analyses  
Enrichment of gene sets was performed using the GSEA algorithm as 
described in Subramanian et al.321.  Enrichment for repression in mutant EZH2 
samples was assessed using the GSEA algorithm against a gene list pre-
ranked for log2 ratio of expression from wild-type EZH2 samples to expression 
from mutant EZH2 samples. Enrichment for responsiveness to EZH2 inhibition 
was assessed against a gene list pre-ranked for log2 ratio of expression after 
GSK343 treatment to expression after GSK669 treatment.  
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Gene Category Enrichment Analysis  
Unsupervised pathway analysis was performed using information-theoretic 
pathway analysis approach as described in Goodarzi et al322.   Briefly, 
pathways that are informative about non-overlapping gene groups were 
identified.  Pathways annotations were used from the Biological Process 
annotations of the Gene Ontology database (http://www.geneontology.org) 
and signature categories from the Staudt Lab Signature database323.  Only 
human-curated annotations were used from the Gene Ontology database and 
only pathways with 5 genes or more, and with 300 genes or less were 
evaluated.  This pathway analysis estimates how informative each pathway is 
about the target gene groups, and applies a randomization-based statistical 
test to assess the significance of the highest information values.  We use the 
default significance threshold of p<0.005.  We estimated the false discovery 
rate (FDR) by randomizing the input profiles iteratively on shuffled profiles with 
identical parameters and thresholds, finding that the FDR was always less 
than 5%.  For each informative pathway, we determined the extent to which 
the pathway was over-represented in the target gene group, using the 
hypergeometric distribution, as described in Elemento et al324.  A supervised 
analysis was also performed by identifying genes upregulated 1.5-fold among 
plasma cells (three RNAseq replicates) or memory cells (three RNAseq 
replicates) compared to GCB cells (four RNAseq replicates).  The significance 
of over-representation among these supervised categories was determined 
using the hypergeometric distribution.  
GCB-DLBCL patient clustering dendrogram  
GCB-DLBCL patient samples were separated into three groups: samples with 
wild-type EZH2 and EZH2 expression in the top quartile, samples with wild-
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type EZH2 and EZH2 expression in the bottom quartile, and samples with 
mutant EZH2.  Gene expression profiles of GCB cell bivalent genes showing 
repression in GCB-DLBCL with mutant EZH2 were analyzed using Euclidian 
distance and Ward’s minimum variance method.  
Bone marrow transplantation  
Murine bone marrow transplantation assays were performed as described 
previously325.  Briefly, bone marrow cells from 6-8 week old male donors were 
harvested and, for Figure S8C-S8I, cells were transduced with viral 
supernatants containing either pRetroX-IRES-ZsGreen1 empty vector, 
pRetroX-EZH2WT-IRES-ZsGreen1, or pRetroX- EZH2Y641F-IRES-ZsGreen1.  
Either 750,00 or 1e+06 bone marrow cells of each type were injected into the 
tail veins of lethally irradiated female C57BL6 mice.  The donor mice from 
Figure 3.7 were BCL2 transgenic animals (VavP-Bcl2)306.  The donor mice 
used in Figure 3.17 were IµBcl6290, Ezh2(Y641F)fl/WT;Cγ1-cre, 
Ezh2(Y641F)fl/WT;Cγ1-cre;IµBcl6 and control littermates.  Nonlethal mandibular 
bleeds were performed monthly after transplantation to assess disease 
severity in all mice.  With the exception of mice euthanized at specific time 
points, all mice were followed until any one of several criteria for euthanizing 
were met, including severe lethargy, more than 10% body weight loss, and 
palpable splenomegaly that extended across the midline, in accordance with 
our Weill Cornell Medical College and Memorial Sloan-Kettering Cancer 
Center Institutional Animal Care and Use Committee–approved animal 
protocols.  Animal care was in strict compliance with institutional guidelines 
established by the Weill Cornell Medical College, the Memorial Sloan-
Kettering Cancer Center, the Guide for the Care and Use of Laboratory 
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Animals (National Academy of Sciences 1996)326, and the Association for 
Assessment and Accreditation of Laboratory Animal Care International.  
IgVH rearrangement analysis  
RT-PCR to evaluate IgVH rearrangements was performed on cDNA of B220 
enriched splenocytes with a set of forward primers that anneal to the 
framework region of the most abundantly used IgVH gene families and reverse 
primers located in the JH1-4 gene segments327. 
Mice xenotransplant  
Six- to eight-week old male SCID mice housed in barrier environment were 
subcutaneously injected in the left flank with 1e+07 human DLBCL cells 
(SUDHL6 and WSU-DLCL2).  Tumor volume was monitored every other day 
using electronic digital calipers in 2 dimensions.  Tumor volume was 
calculated using the following formula: tumor volume (mm3) = (smallest 
diameter2 × largest diameter)/2.  When tumors reached a palpable size (<50 
mm3 after 17 days of cell injection), the mice were randomized to 2 different 
treatment arms.  One group was injected intraperitoneally with vehicle (20% 
captisol) and the other group received GSK503 or GSK126 administered daily 
at a concentration of 80 mg/kg/day for 7 to 9 consecutive days.  On day 7 or 9 
of treatment the mice from each group were randomized to 2 arms, generating 
4 different treatment arms.  Two groups were treated with 12 mg/kg/day FX1 
or RI-BPI for additional 15 days.  Drugs were administered in a concurrent 
schedule by 2 intraperitoneal injections 4–6 hours apart.  All mice were 
euthanized when at least 2 out of 10 tumors reached 20 mm in any dimension 
(equivalent to 1–1.5 grams), which was generally on day 20 to 24 of the 
treatment schedule.  
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EZH2 small molecule inhibitors  
GSK343 was synthesized as described in Verma et al328.  GSK126 was 
synthesized as described in McCabe et al.93, and GSK503, as described in 
(Beguelin et al., 2013).  
BCL6 inhibitors  
FX1 small molecule was synthesized as described in Cardenas et al.280, based 
on compound 79-6329. 
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